

Temeljem članka 8. i 27. Statuta Grada Zadra ("Glasnik Grada Zadra", broj: 9/09, 28/10, 3/13, 9/14 i 2/15-pročišćeni tekst) i članka 6. Odluke o javnim priznanjima ("Glasnik Grada Zadra", broj: 4/07 - pročišćeni tekst i 11/09), **Gradsko vijeće Grada Zadra, na ___ sjednici, održanoj dana _____ 2015. godine, donosi**

ODLUKU

Članak 1.

NAGRADA GRADA ZADRA ZA ŽIVOTNO DJELO dodjeljuje se **gospodinu prof.dr.sc. BORISU LABARU dr.med.** kao zahvalnost za osobiti doprinos gradu Zadru, naročite uspjehe i najviše zasluge na području zdravstva i zdravstvenih znanosti.

Članak 2.

Ova Odluka stupa na snagu danom donošenja.

KLASA: 061-01/15-01/01
URBROJ: 2198/01-1-15-
Zadar, _____ 2015. godine

GRADSKO VIJEĆE GRADA ZADRA

PREDSJEDNIK

Živko Kolega, dr.med.

Grupa građana
Zadar, 10. listopada 2015.

Republika Hrvatska
Grad Zadar
Odjel za dodjelu javnih priznanja
Narodni trg 1, 23000 Zadar

Povodom javnog poziva za podnošenje prijedloga za dodjela javnih priznanja Grada Zadra objavljenog 18. rujna 2015. god. temeljem članka 12. Odluke o javnim priznanjima Grada Zadra ("Glasnik Grada Zadra", br. 4/07 – pročišćeni tekst i 11/09), podnosimo **prijedlog za dodjelu Nagrade grada Zadra za životno djelo prof. dr. sc. Borisu Labaru, dr. med.**

Ime i prezime predloženika: Boris Labar

Adresa predloženika: Hećimovićeva 6, 10000 Zagreb

Tel.: 01 23 155 19, mob.: 091 45 66 909

Priložena dokumentacija:

- Prijedlog Grupe građana
- Popis imena Grupe građana s vlastoručnim potpisom
- Pismena suglasnost predloženika
- Životopis predloženika
- Popis znanstvenog, stručnog i javnog opusa predloženika

GRUPA GRAĐANA
Zadar, 10. listopada 2015.

GRAD ZADAR
Odbor za dodjelu javnih priznanja
23000 ZADAR, Narodni trg 1

Poštovani,

Cijenimo i koristimo mogućnost da kao Grupa građana izrazimo svoje mišljenje o osobi koja je u svom osobnom i profesionalnom životu i radu posvjedočila izvrsnost kao pojedinac, a nadasve izuzetan stručnjak. Na tom putu u koji je uloženo puno znanja i odricanja gradile su se vrijednosti koje ostaju trajno djelo našeg sugrađanina koji se izdvojio kao hrvatski i svjetski hematolog. Grupa građana kao dio zadarske sredine kojoj je pripadao i trajno ostao vjeran s posebnim senzibilitetom i poštovanjem predlaže

Prof. dr. sc. Borisa Labara, dr. med.

za


**NAGRADU GRADA ZADRA
ZA ŽIVOTNO DJELO**

Dr Boris Labar pripada plejadi znanstvenih, pedagoških, publicističkih, humanitarnih pojedinaca koji su zadužili ne samo matičnu sredinu već i puno šire. Bio je i ostao borac za život što je u svojoj plodonosnoj karijeri nesebično radio.

Grad Zadar je u svojoj povijesnoj, kulturnoj, znanstvenoj, stručnoj, sportskoj i inoj izvrsnosti prepoznat upravo preko zaslužnih pojedinaca, dr. Labar je jedan od njih. Zadarska sredina već dugo apostrofira svoje zaslužnike, vjerujemo da će odluka o visokom priznanju biti čast predloženiku i gradu Zadru u cjelini.

Ovom časnom prijedlogu pridružuje se i zlatna generacija maturanata Gimnazije Vladimira Nazora u Zadru (1965. – 2015.) kojoj dr. Labar pripada.














Mr. sc. Maja Maržić/Mazzi, dr. med.



GRUPA GRAĐANA KOJA SVESRDNO PODRŽAVA KANDIDATURU

Prof. dr. sc. Borisa Labara, dr. med.

ZA NAGRADU GRADA ZADRA ZA ŽIVOTNO DJELO

ime i prezime	zvanje - zanimanje	potpis
Prof. dr. sc. Igor Francetić, dr. med.	Specijalist interne medicine i kliničke farmakologije	
Prof. dr. sc. Ognjen Kraus, dr. med.	Specijalist urologije	
Prof. dr. sc. Dijana Vican	Rektorica Sveučilišta u Zadru	
Prof. dr. sc. Erma Ivoš	Sveučilišna profesorica u miru	
Prof. Nikola Bašić, dipl. ing. arh.	Sveučilišni profesor GAG-e, Sveučilište u Splitu	
Mr. sc. Marija Obad, prof. Visoke škole	Sveučilišna profesorica u miru	
Mr. sc. Maja Maržić Mazzi, dr. med.	Specijalistica medicinske citologije u miru	
Dr. sc. Darija Breyer, med. biok.	Specijalistica medicinske biokemije	
Višnja Jelić Mück, dipl. ing. arh.	Državna tajnica Ministarstva zaštite okoliša u miru	
Živko Dijan, dr. dent. med.	Specijalist dječje dentalne medicine i preventive	
Zvonko Vidošević, dipl. ing. elek.	Ing. elektrotehnike u miru	
Goran Novaković	sportski djelatnik	
Akademik Vjekoslav Jerolimov, dr. dent. med.	Sveučilišni profesor u miru	

Boris Labar
HEGEDUŠIĆEVA 6.
10.000 ZAGREB
Tel. 091 4566 909
E-mail: boris.labar@inet.hr

Grad ZADAR
Odbor za dodjelu
jona priiznanje.

Poštovani,
Suglasan sam s prijateljom stupice
gratons. za dodjelu jona priiznanje
grade Zadar.

S poštovanjem

Zi W

u Zagrebu, 6.10.2015.


Boris Labar
Hegedušićeva 6.
10.000 Zagreb
Tel. 091 45 66 909
Mail: boris.labar@inet.hr

Grad Zadar
Odbor za dodjelu
Javnih priznanja

Poštovani,

Suglasan sam s prijedlogom skupine građana za dodjelu javnog priznanja grada Zadra.

S poštovanjem,

Boris Labar


U Zagrebu 6.10. 2015.

Boris Labar

Životopis

<u>Mjesto i datum rođenja:</u>	Zadar, 1947.
<u>Edukacija:</u>	
1965	Gimnazija u Zadru
1965-70	Medicinski fakultet, Sveučilišta u Zagrebu,
1971-72	Pripravnički staž, Klinička bolnica „Sestre Milosrdnice, Zagreb
1972	Poslijediplomski studij iz „Kliničko Laboratorijske korelacije“, Medicinski fakultet Sveučilišta u Zagrebu (1972-1975)
1972-76	Specijalizacija iz Interne medicine
1977	Asistent u Katedri za Internu Medicinu, Medicinskog fakulteta, Sveučilišta u Zagrebu.
1978	Magistar znanosti: „Klinička vrijednost određivanja metabolita difosfogliceratnog ciklusa i reduciranog glutationa u eritrocitu nasljednih hemolitičkih anemija“
1982	Doktorski rad “Piruvat kinaza u akutnih leukemija“
1982-85	Voditelj Centra za Transplantaciju koštane srži, Zavoda za hematologiju, Klinike za unutrašnje bolesti, Klinički bolnički centar Zagreb i Medicinskog fakulteta Sveučilišta u Zagrebu.
1982-85	Voditelj istraživač – znanstvenog projekta “ <i>Clinical and Experimental Bone Marrow Transplantation</i> ” No SFC-02-092N, USA-Yugoslav Joint fund
1982	Član Međunarodnog Registra za liječenje transplantacijom koštane srži (engl. <i>International Bone Marrow Transplant Registry – IBMTR</i>)
1982-90	Voditelj istraživač – znanstvenog projekta “Transplantacija koštane srži” Ministarstvo znanosti Republike Hrvatske.
1984	Docent u Katedri za Internu Medicinu, Medicinskog fakulteta, Sveučilišta u Zagrebu.
1985-2012	Pročelnik Zavoda za hematologiju, Klinike za unutrašnje bolesti KBC, Zagreb
1985-2012	Član Europske grupe za transplantaciju koštane srži (engl. <i>European Bone Marrow Transplant Group – EBMTG</i>)
1986-1989	Voditelj poslijediplomskog studija iz Hematologije, Medicinskog fakulteta, Sveučilišta u Zagrebu.
1987	Voditelj – Znanstvenog sastanka “ <i>New Trends in the Treatment of Acute Leukemia</i> ” organizatori Europska

- onkološka škola iz Milana, Italija i Zavod za hematologiju, Kliničkog bolničkog centra i Medicinskog fakulteta, Sveučilišta u Zagrebu
- 1987 Član međunarodnog društva za Eksperimentalnu hematologiju
- 1989 Voditelj – Znanstvenog sastanka “*New Trends in the Treatment of Acute Leukemia*” organizatori Europska onkološka škola iz Milana, Italija i Zavod za hematologiju, Kliničkog bolničkog centra i Medicinskog fakulteta, Sveučilišta u Zagrebu
- 1989 Voditelj istraživač – znanstvenog projekta “*Clinical Bone Marrow Transplantation*” No PN917 USA-Yugoslav Joint Fund
- 1990-2005 Izvanredni profesor iz Interne medicine, Medicinskog fakulteta, Sveučilišta u Zagrebu.
- 1991 Član osnivač Europskog hematološkog društva.
- 1991 Član Medicinskog savjeta, Europske onkološke škole, Milano, Italija, ureda u Beču.
- 1991-2005 Izvanredni profesor iz Hematologije, Farmaceutsko Biokemijskog fakulteta, Sveučilišta u Zagrebu.
- 1993 Voditelj – Znanstvenog sastanka “*New Trends in the Treatment of Acute Leukemia*” organizatori Europska onkološka škola iz Milana, Italija i Zavod za hematologiju, Kliničkog bolničkog centra i Medicinskog fakulteta, Sveučilišta u Zagrebu
- 1994 - 1998 Predsjednik Društva za hematologiju i transfuziju, Hrvatskog liječničkog zbora.
- 1995 Voditelj – Znanstvenog sastanka “*New Trends in the Treatment of Acute Leukemia*” organizatori Europska onkološka škola iz Milana, Italija i Zavod za hematologiju, Kliničkog bolničkog centra i Medicinskog fakulteta, Sveučilišta u Zagrebu
- 1996 Voditelj – Znanstvenog sastanka “*Stem cell transplants for solid tumours*” organizator Europska onkološka škola, ured u Beču.
- 1999 Voditelj – Znanstveni sastanak “*News in Cytokines*” organizator Europska onkološka škola, ured u Beču.
- 1999 Voditelj – Znanstveni sastanak “*Infections in Immunocompromised Patients*” Dubrovnik
- 2000 Počasni član hematološkog društva Mađarske i Slovenije.
- 2000 Član uredničkog odbora časopisa “*Lymphoma*”
- 2000-2004 Dekan, Medicinski fakultet, Sveučilišta u Zagrebu
- 2005-2012 Redoviti profesor iz Interne medicine, Medicinskog fakulteta, Sveučilišta u Zagrebu.

2007	Voditelj – znanstveni sastanak – „Leukemia and Lymphoma” organizator MD Anderson Houston I Zavod za hematologiju Klinički bolnički centra i medicinski fakultet Sveučilišta u Zagrebu.
2009-2012	Predsjednik Hrvatske kooperativne grupe za liječenje hematoloških bolesti – KROHEM
2010-2012	Predsjednik kooperativne grupe za liječenje leukemija srednje i istočne Europe (engl. „ <i>Central and Eastern European Leukemia Group</i> ” – CELG),
2011	Voditelj – znanstveni sastanak – „Leukemia and Lymphoma” organizator MD Anderson Houston I Zavod za hematologiju Klinički bolnički centra i medicinski fakultet Sveučilišta u Zagrebu.
2012-danas	Centar za ekspertnu medicinu, Zagreb.
2013.	Nagrada Međunarodnog Centra za istraživanje transplantacije krvi i koštane srži, Milwaukee, USA.
2013.	Počasni član Europskog društva za transplantaciju krvotvornih matičnih stanica.
2014.	Nagrada grada Zagreba za životno djelo
2014.	Nagrada za životno djelo Hrvatskog sabora u području biomedicinskih znanosti.
2015.	Voditelj – znanstveni sastanak – „Leukemia and Lymphoma” organizator MD Anderson Houston I Zavod za hematologiju Klinički bolnički centra i medicinski fakultet Sveučilišta u Zagrebu.
2015.	Profesor emeritus, Medicinski fakultet, Sveučilišta u Zagrebu.

Od 1974, publicirao je više od 405 znanstvenih i stručnih radova, s više od 140 znanstvenih publikacija u CC časopisima, koji su citirani 2450 puta.

Gost predavač u više institucija:

- Grosharden University Hospital Munchen
- The Fred Hutchinson Cancer Center, Seattle, WA, USA
- St Louis Hospital, Paris, France
- NCI, Bethesda, USA
- University Hospital, Salt Lake City, USA
- University Hospital, Leyden, The Netherlands
- Klinički Centar Ljubljana
- Hematologija, Katowice, Poljska
- MD Anderson Cancer Research Center, Houston, USA

Ostale aktivnosti:

1993	Član predsjedništva HAVK Mladost
1994-2001	Liječnik Hrvatske vaterpolo reprezentacije i vaterpolista Mladosti.
1996-danas	Predsjednik Zdravstvene komisije Hrvatskog olimpijskog odbora.
2005-danas	Član UO Hrvatskog vaterpolskog Saveza
2014-danas	Predsjednik HAVK Mladost

Zagreb, listopad 2015

Boris Labar, M.D., Ph.D.

P R I L O G

Boris Labar, redovni profesor u trajnom zvanju, Medicinski fakultet, Sveučilišta u Zagrebu

A. UKUPAN BROJ RADOVA

Predloženik je publicirao 130 znanstvenih radova (125 u CC), 71 rad u ostalim indeksima i 13 stručna rada.

AI.

a) Radovi objavljeni u časopisima koji su referirani u svjetskim bazama

1. Labar B, Stavljenić A, Jusufhodžić L. Red Cell Pyruvat Kinase in Acute Leukemia. *Enzyme* 1984; 32:178-183.
2. Labar B, Bogdanić V, Kaštelan A, Vrtar M, Grgić-Markulin Lj, Balabanić-Kamauf B, Francetić I, Dobrić I, Grgičević D, Kerhin-Brkljačić V, Boban D, Zimonja-Krišković J, Boranić M. Experience with bone marrow transplantation for severe aplastic anemia and leukemia. Two years experience with 34 patients in Zagreb (Yugoslavia). *Biomedicine & Pharmacotherapy* 1986; 40:332-335.
3. Labar B, Bogdanić V, Plavšić F, Francetić I, Dobrić I, Kaštelan A., Grgičević D., Vrtar M., Grgić-Markulin Lj., Balabanić-Kamauf B., Boban D., Kerhin-Brkljačić V., Boranić M.: Cyclosporin neurotoxicity in patients treated with allogeneic bone marrow transplantation. *Biomedicine & Pharmacotherapy*. 1986; 40:148-150.
4. Woolhandler S., Himmelstein D.U., Labar B., Lang S.: Transplanted technology: Third world options and first world science, *New Engl J Med*, 1987; 317:504-506.
5. Grahovac B. Labar B., Stavljenić A.: Phenotyping of Phosphoglucomutase (PGM1) isoenzymes - a new method for the follow-up of chimerism after bone marrow transplantation. *Enzyme*. 1988; 40:37-39.
6. Čorišćec D, Plavšić F, Stavljenić A, Bogdanić V, Labar B. Urinary-excretion of beta-2-mikroglobulin after administration of cyclosporine in patients treated with Bone Marrow Transplantation. *Acta Pharm Jug*. 1988; 38:245-250.
7. Woolhandler S., Himmelstein D.U., Labar B., Lang S.: Obstacles to transplantation technology - reply, *New Engl J Med*, 1988; 318:451.
8. Batinić D, Boranić M, Labar B, Bogdanić V, Nemet D, Boban D, Kardum I, Mrsić M, Jakšić B. Surface marker analysis in routine laboratory classification diagnosis of leukemia. *Period Biol*. 1988; 90:43-47.
9. Grahovac B., Labar B., Stavljenić A.: Subtyping of Erythrocyte Phosphoglucomutase-1 as a Genetic Marker for Bone-Marrow Engraftment and Hematopoietic Chimerism after Allogeneic Bone-Marrow Transplantation in a Patient with Acute Lymphoblastic Leukemia. *Clin Chem*. 1988; 34:2586-2588.
10. Batinić D., Tindle R., Boban D., Tiefenbach A., Rajić Lj., Labar B., Nemet D.: Expression of haematopoietic progenitor cell-associated antigen BI-3C5/CD34 in leukaemia. *Leuk Res*. 1989; 13:83-85.

11. Batinić D., Pavletić Ž., Kolevska T., Bogdanić V., Žalud I., Nemet D., Marušić M., Labar B.: Lymphocyte subsets in normal human bone marrow harvested for routine clinical transplantation. *Bone Marrow Transplantation*. 1989; 4:229-232.
12. Batinić D., Marušić M., Pavletić Ž., Bogdanić V., Užarević B., Nemet D., Labar B.: Relationship between differing volumes of bone marrow aspirates and their cellular composition. *Bone Marrow Transplantation*. 1990; 6:103-107.
13. Pavletić Ž., Labar B., Bogdanić V., Nemet D., Mrišić M., Stavljenić A., Čvorišćec D., Presečki V., Petrovečki M. Serum neopterin in patients receiving Bone-Marrow Transplant. *Bone Marrow Transplantation*. 1989; 4(suppl 3.):97-98.
14. Mrišić M., Labar B., Bogdanić V., Nemet D., Pavletić Ž., Plavšić F., Dobrić I., Kaštelan A., Marušić M., Zupančić-Šalek S., Radman I., Francetić I., Aurer I. Combination of cyclosporine and methotrexate for prophylaxis of acute graft versus host disease after allogeneic bone marrow transplantation for leukaemias. *Bone Marrow Transplant* 1989;4(suppl 3):95-6.
15. Grahovac B., Labar B., Stavljenić A. The type of chimerism after allogeneic bone marrow transplantation as detected by isoenzymatic polymorphism. *Bone Marrow Transplantation*, 1989; 4(Suppl. 3.):93-94,
16. Nemet D., Labar B., Bogdanić V., Kolevska T., Skodlar J., Mrišić M., Pavletić Ž., Kalenić S., Vrtar M., Marušić M., Markulin-Grgić Lj., Boban D., Francetić I.: Treatment of acute leukaemia with intensive radiochemotherapy and autologous bone marrow transplantation - Zagreb experience. *Bone Marrow Transplantation*, 4(Suppl.3.):90-91, 1989.
17. Bogdanić V., Labar B., Nemet D., Mrišić M., Pavletić Ž., Aurer I. Allogeneic bone marrow transplantation for ALL in Zagreb. *Bone Marrow Transplant* 1989;4(suppl 3): 88-9.
18. Labar B., Nemet D., Minigo H., Bogdanić V., Jakšić B., Malešević M., Mrišić M.: Aclarubicin in the treatment of de-novo acute myelocytic leukaemia. *Bone Marrow Transplantation*, 1989; 4(Suppl. 3.):45-46.
19. Nemet D., Labar B., Bogdanić V., Hauptman E., Jakšić B., Minigo H., Sertić D., Mrišić M., Pavletić Ž., Kovačević J i sur. High dose cytosine arabinoside in the treatment of adult acute myelogenous leukaemia. *Bone Marrow Transplant* 1989;4(suppl 3):42-4.
20. Gerhartz HH, Visani G, Delmer A, Zwierzina H, Ribeiro M, Jacobs A, Marcus R, Baumelou M, Fiere D, Labar B i sur. Low dose Ara-C plus granulocyte/macrophage colony-stimulating factor in the treatment of myelodysplastic syndromes. *Bone Marrow Transplant* 1989;4(suppl 3):26-7.
21. Bogdanić V., Labar B., Mrišić M., Nemet D., Serventi-Seiwerth R.: Low dose Ara-C in the treatment of myelodysplastic syndromes. *Bone Marrow Transplantation*. 4(Suppl.3):26-27, 1989.
22. Mrišić M., Labar B., Bogdanić V., Nemet D., Pavletić Ž., Plavšić F., Dobrić I., Marušić M., Francetić I., Kaštelan A., Kalenić S., Vrtar M., Grgić-Markulin L., Aurer I.: Combination of cyclosporin and methotrexate for prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation for leukemia. *Bone Marrow Transplantation*. 1990; 6:137-141.

23. Batinić D, Marušić M, Pavletić Ž, Bogdanić V, Užarević B, Nemet D, Labar B. Relationship between differing volumes of bone-marrow aspirates and their cellular composition. *Bone Marrow Transplantation*. 1990; 6:103-107.
24. Sučić M., Boban D., Marković-Glamočak M., Petrovečki M., Marušić M., Labar B.: Prognostic significance of cytochemical analysis of leukemic M2 blasts. *Med Oncol & Tumor Pharmacother*. 1992; 9:41-45.
25. Gerhartz HH, Marcus R, Delmer A, Zwierzina H, deWitte T, Jacobs A, Visiani G, Fiere D, Sonneveld P, Labar B, Hoffbrand AV, Fenaux P, Hayat M, Thyss A, Debucher L, Coiffier B, Sizoo W, Willemze R, Ribeiro M, Suciú S, Solbu G, Stern A, Zittoun R for the EORTC Leukemia Group: Treatment of Myelodysplastic Syndromes (MDS) and high leukaemic risk with low-dose Cytosine Arabinoside (LD-AraC) plus Granulocyte-Stimulating Factor (rh GM-CSF). *Infection*, 20(suppl 2):116-123. 1992.
26. Stryckmans P, de Witte T, Marie JP, Fillet G, Peetermans M, Bury J, Muus P, Andrien JM, Hayat M, Jaksic B, Labar B, Debusschier L, Solbu G, Suciú S, Zittoun R. Therapy of adult ALL- overview of 2 successive EORTC studies (ALL-2 and ALL-3). *Leukemia*; 6(suppl 2.):199-203.
27. Willemze R., van der Lely N., Zwierzina H., Suciú S., Solbu G., Gerhartz H., Labar B., Visiani G., Peetermans M.E., Jacobs A., Stryckmans P., Fenaux P., Haak H.L., Ribeiro M.M., Baumelou E., Baccarani M., Mandelli F., Jaksic B., Louwagie A., Thyss A., Hayat M., de Cataldo F., Stern A.C., Zittoun R., on behalf of the EORTC Leukemia Cooperative Group: A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (Gm-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. *Ann Hematol*. 1992; 64:173-180.
28. Jakić-Razumović J., Užarević B., Petrovečki M., Marušić M., Radman I., Labar B.: AgNORs predictive value of prognosis in Non-Hodgkin's Lymphoma comparison with flow cytometric cell cycle analysis, *Leuk Lymphoma*. 1992; 7:165-170.
29. Labar B., Bogdanić V., Nemet D., Mrsić M., Vrtar M., Grgić-Markulin Lj., Kalenić S., Vujasinović S., Presečki V., Jakić-Razumović J., Marušić M.: Total body irradiation with or without lung shielding for allogeneic bone marrow transplantation. *Bone Marrow Transplantation*. 1992; 9:343-347.
30. Labar B., Bogdanić V., Nemet D., Kovačević-Metelko J., Mrsić M., Pavletić Ž., Šalek-Zupančič S., Radman I., Aurer I.: Antilymphocyte globulin for treatment of pure red cell aplasia after major ABO incompatible marrow transplant. *Bone Marrow Transplant*. 1992; 10:471-472.
31. Link H., Boogaerts M.A., Carella A.M., Ferrant A., Gadner H., Gorin N.C., Harabach I., Harrousseau F., Herve P., Holldack J., Kolb H.J., Krieger O., Labar B., Linkesch W., Mandelli F., Maraninchi D., Naprastek E., Nicolay U., Niederwieser D., Reiffers J., Rizzoli V., Siegert W., Vernant J.P., de Witte T.: A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high dose chemotherapy and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. *Blood*. 1992; 80:2188-2195.

32. Boban D, Sučić M, Marković-Glamočak M, Užarević B, Batinić D, Marušić M, Nemet D, Labar B, Hitrec V. Correlation of morphological FAB classification and immunophenotyping: value in recognition of morphological, cytochemical and immunological characteristics of mixed leukaemias, *Eur J Cancer* 1993; 29A:1167-72.
33. Mrsić M, Nemet D, Labar B, Bogdanić V, Radman I, Zupančić-Šalek S, Kovačević-Metelko J, Aurer I, Maravić N. Chemotherapy versus Allogeneic bonem marrow transplantation in adults with acute lymphoblastic leukemia. *Transplant Proc.* 1993; 25:1268-1270.
34. Labar B., Mrsic M., Pavletic Z., Bogdanic V., Nemet D., Aurer I., Radman I., Filipovic-Grcic N., Sertic D.: Prostaglandin E2 for prophylaxis of oral mucositis following bone marrow transplantation. *Bone Marrow Transplant.* 1993; 11:379-382.
35. Bogdanic V., Nemet D., Kastelan A., Latin V., Petrovecki M., Brkljacic-Surkalovic LJ., Kerhin-Brkljacic V., Aurer I., Konja J., Mrsic M., Kalenic S., Labar B.: Umbilical cord blood transplantation in a patient with Philadelphia chromosome positive chronic myeloid leukemia, *Transplantation.* 1993; 56:477-479.
36. Zittoun R, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Ferrini R, Visani G, Ceronia E, Stryckmans P, Marmont A, Hayat M, Umlauf F, Rotoli B, peetermans M, Papa LP, Petti MC, Dardenne M, Solbu G, Vegna ML, Suci S. EORTC-GIMEMA AML 8 protocol – a phase III study on autologous bone-marrow transplantation in acute myelogenous leukemia (AML), *Leuk Lymph* 1994; 13(Suppl 1):101.
37. Gerhartz HH, Marcus R, Delmer A, Zwierzina H, Suci S, Dardenne M, Solbu G, de Witte T, Jacobs A, Visani G, Fiere D, Sonneveld P, Labar B, Hoffbrand AV, Fenaux P, Hayat M, Thyss A, Debusscher L, Coiffier B, Sizoo W, Willemze R, Ribeiro M, Mandelli F, Burghouts G, Cauchie C. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (RHGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia, *Leukemia* 1994; 8:16-23.
38. Aurer I, Nemet D, Užarević B, Hitrec V, Mrsić S, Grgić M, Boban D, Zupančić-Šalek S, Radman I, Labar B. Mediastinal malignant teratoma and acute myeloid leukemia in a patient with a Klinefelter's syndrome - comparison of DNA content in the two malignancies, *Acta Oncol* 1994, 33: 705-6.
39. Aurer I, Labar Nemet D, Ajduković R, Bogdanić V, Gale RP. High incidence of conservative RAS mutations in acute myeloid leukemia, *Acta Haematol* 1994; 92: 123-125.
40. Maravić N, Bogdanić V, Aurer I, Nemet D, Labar B. Severe hyperlipidemia following treatment with PUVA for acute skin GVHD, (Correspondence), *Bone Marrow Transplantation* 1994, 14: 173.
41. Labar B, Mrsić M, Nemet D, Bogdanić V, Radman I, Boban D, Batinić D, Kalenić S, Vrtar M, Grgić - Markulin Lj, Kaštelan A, Marušić M. Allogeneic bone marrow transplantation versus chemotherapy for patients with acute myelogenous leukaemia in first remission, *Transplantationsmedizin* 1994, 6: 235-239.

42. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, Hayat M, Stryckmans P, Rotoli B, Leoni P, Peetermans ME, Dardenne M, Vegna ML, Petti MC, Solbu G, Suci S for the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'adulto (GIMEMA) Leukemia Cooperative Groups: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia, *New Engl J Med* 1995; 332:217-223.
43. Nemet D, Grahovac B, Labar B, Mrsić M, Radman I, Bogdanić V, Hitrec V, Zaher D, Aurer I, Sertić D, Bošnjak A, Boban D. Molecular monitoring of minimal residual disease in acute promyelocytic leukaemia by the polymerase chain reaction assay for the PML/RAR α (retinoic acid receptor- α fusion transcript in patients treated with all-trans retinoic acid followed by chemotherapy, *Haematologica* 1995; 80: 238-240.
44. Nemet D, Labar B, Bogdanić V, Skodlar J, Petrovečki M, Mrsić M, Maravić N, Šneller V, Radman I, Kovačević-Metelko J, Sertić D, Serventi-Seiwerth R. Autologous bone marrow transplantation for haematological malignancies - Experience of the Centre of Zagreb, *Wien Med Wschr* 1995; 145:61-64.
45. Bogdanić V, Aurer I, Hitrec V, Boban D, Nemet D, Zupančić-Šalek S, Labar B. Donor buffy-coat infusion and chemotherapy for leukemia in relapse after marrow transplantation, *Haematologica* 1995; 80:338-340.
46. Jandrić M, Kalenić S, Labar B, Nemet D, Jakić-Razumović J, Mrsić M, Plečko V, Bogdanić V. An autopsy study of systemic fungal infections in patients with hematological malignancies, *Eur J Clin Microbiol Infect Dis* 1995; 14:768-774.
47. De Witte T, Suci S, Selleslag D, Labar B, Roozendaal K, Zittoun R, Ribeiro M, Kurstjens R, Hayat M, Dardenne M, Solbu G, Muus P. Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: A phase-II study (no 06901) of the EORTC Leukemia Cooperative Group. *Ann Hematol* 1996; 72:119-124.
48. Labar B, Masszi T, Morabito F, Mistrik M, Holowiecki J, Bogdanić V, Nemet D, Mrsić M, Krieger O, Lutz D on behalf of International Group for Chemo-Immunotherapy, Vienna, Austria. Allogeneic bone marrow transplantation for acute leukaemia - IGCI experience. *Bone Marrow Transplant* 1996; 17:1009-1012.
49. Keating S, Suci S, deWitte T, Mandelli F, Willemze R, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, Hayat M, Stryckmans P, Rotoli B, Leoni P, Peetermans ME, Dardenne M, Vegna ML, Petti MC, Solbu G, Zittoun RA for the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'adulto (GIMEMA) Leukemia Cooperative Groups: Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: An analysis of the EORTC-GIMEMA AML 8A Trial. *Bone Marrow Transplant* 1996; 17:993-1001.
50. Brugiattelli M, Holowiecka B, Dmoszynska A, Krieger O, Planinc-Peraica A, Labar B, Callea V, Morabito F, Jakšić B, Holowiecki J, Lutz D. 2-chlorodeoxyadenosine treatment in non-Hodgkin lymphoma and B-cell chronic

- lymphocytic leukemia resistant to conventional chemotherapy – results of a multicentric experience, *Ann Hematol* 1996;73:79-84.
51. Gregurek R, Labar B, Mrsić M, Batinić D, Ladika I, Bogdanić V, Nemet D, Skerlev M, Jakić-Razumović J, Klain E. Anxiety as a possible predictor of acute GvHD. *Bone Marrow Transplant* 1996; 18:585-589
 52. Willemze R, Suci S, Archimbaud E, Muus P, Stryckmans P, Louwagie EA, Berneman Z, Tjean M, Wijermans P, Dohner H, Jehn U, Labar B, Jakčić B, Dardenne M, Zittoun R. A randomized phase II study on the effects of 5-aza-2-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia – an EORTC leukemia cooperative group phase II study (06893), *Leukemia* 1997;11(Suppl 1):S24-S27.
 53. Bogdanić V, Aurer I, Labar B, Hitrec V, Nemet D, Mrsić M. Treatment of chronic myeloid leukemia in relapse after umbilical cord blood transplantation. *Haematologica*, 1998; 83:575-76.
 54. Labar B, Nemet D, Mrsić M, Bogdanić V, Kaštelan A, Boban D, Kalenić S, Radman I, Batinić D, Vrtar M, Grgić-Markulin Lj, Maravić N. Autologous versus Allogeneic Marrow Transplantation for Patients with Acute Myeloid Leukemia in 1st Remission. *Cancer Research Therapy Control* 1998, 5:143-149.
 55. Čečuk-Jeličić E, Grubić Z, Žunec R, Labar B, Kerhin-Brkljačić V, Kaštelan A. Implication of molecular analysis of HLA-A*02 subtyping for unrelated bone-marrow donor selection. *Bone Marrow Transplant* 1998;4:S27-30.
 56. Fučić A, Špacir Z, Barković D, Jazbec A, Mijić A, Labar B. Relative lymphocytosis – Disorder caused by Occupational Exposure to Vinyl Chloride Monomer. *Bull Environ Contam Toxic* 1998, 61:583-590.
 57. Sučić M, Boban D, Marković-Glamočak M, Bogdanić V, Nemet D, Labar B, Čvorišćec D, Plavšić F, Štoos-Vejić T, Mrsić M. Relation Between Urinary Cytology Abnormalities and Cyclosporine A Therapy in Bone Marrow Transplant Recipients. *Renal Failure* 1998, 20:613-620.
 58. Keating S, de Witte T, Suci S, Willemze R, Hayat M, Labar B, Resegotti L, Rossi Ferrini P, Caronia F, Dardenne M, Solbu G, Petti MC, Vegna ML, Mandell F, Zittoun RA. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: An analysis of the AML 8A study of the EORTC Leukemia Cooperative Group and GIMEMA. *Brit J Haematol* 1998, 102:1344-1353.
 59. Zadro R, Sučić M, Aurer I, Metelko-Kovačević J, Labar B, Stavljenić-Rukavina A. Analysis of clonality in T-lymphoproliferative diseases by multiplex PCR. *Clin Chem Lab Med* 1998;36(8):637-639.
 60. Labar B, Nemet D, Mrsić M, Bogdanić V, Batinić D, Golubić-Čepulić B, Petrovečki M, Radman I, Aurer I, Sertić D. Autologous stem cell transplantation in the treatment of acute leukemias. *Zdrav Vestn* 1998, 67:9-10.
 61. Stanović S, Boranić M, Petrovečki M, Nemet D, Skodlar J, Golubić-Čepulić B, Batinić D, Labar B. Thiorphan stimulates clonal growth of GM-CFU in short term cultures of bone marrow from a healthy donor and from patients with non-Hodgkin lymphoma. *Biomed & Pharmacother* 1998;52:397-402.
 62. Sučić M, Boban D, Marković-Glamočak M, Užarević B, Zadro R, Petrovečki M, Ries S, Gjadrov K, Golemović M, Stavljenić-Rukavina A, Labar B, Batinić D.

- Double immunoenzymatic APAAP staining for the detection of leukaemia-associated immunophenotypes. *J Haematother & Stem Cell Res* 1999;8:635-643.
63. Maravić N, Nemet D, Tomašković Z, Dobrić I, Skerlev M, Bogdanić V, Mrsić M, Šneller V, Skodlar J, Petrovečki M, Batinić D, Boban D, Labar B. GVHD induced by cyclosporine a following ABMT did not improve the outcome in haematological malignancies. *Cancer Res Ther and Control* 1999;10:31-38.
 64. Mrsić S, Labar B, Mrsić M, Nemet D, Bogdanić V, Batinić D, Boban D, Marković-Glamočak M, Sučić M, Užarević B, Stavljenić-Rukavina A. Prognostic significance of chromosome findings in de-novo acute myelogenous leukaemia. *Cancer Res Ther* 1999;00:1-10.
 65. Janda SS, Boranić M, Sučić M, Petrovečki M, Golubić-Čepulić B, Aurer I, Labar B. Effects of membrane-metallopeptidase blocking agent thiorphan in long-term cultures of human bone marrow. *Haematologia* 2000;30:289-302.
 66. Stanović S, Boranić M, Petrovečki M, Batinić D, Skodlar J, Nemet D, Labar B. Thiorphan, an inhibitor of neutral endopeptidase/enkephalinase (CD10/CALLA) enhances cell proliferation in bone marrow cultures of patients with acute leukaemia in remission. *Haematologia* 2000;30:1-10.
 67. de Witte T, Suciū S, Verhoef G, Labar B, Archimbaud E, Aul C, Selleslag D, Ferrant A, Wijermans P, Mandelli F, Amadori S, Jehn U, Muus P, Boogaerts M, Zittoun R, Gratwohl A, Zwierzina H, Hagemeyer A, Willemze R. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukaemia following MDS. *Blood*, 2001;98:2326-2331.
 68. Oosterveld M, Muus P, Suciū S, Koller C, Verhoef G, Labar B, Wijermans P, Aul C, Fiere D, Selleslag D, Willemze R, Gratwohl A, Ferrant A, Mandelli F, Cortes J, de Witte T, Estey E. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. *Leukemia*, 2002;16:1615-21.
 69. Huić D, Ivančević V, Aurer I, Dodig D, Nemet D, Labar B, Poropat M, Munz DL. Bone marrow immunoscintigraphy in haematological patients with pancytopenia: preliminary results. *Nucl Med Comm*, 2002; 23:757-63.
 70. Labar B, Bogdanić V, Nemet D, Mrsić M, Serventi-Seiwerth R, Sertić D, Golubić-Cepulić B, Vrtar M, Santek F, Batinić D, Mikulić M, Pulanić D. Allogeneic stem cell transplantation in treatment of aggressive lymphomas: case series. *Croat Med J*. 2002; 43:565-8.
 71. Radman I, Kovacević-Metelko J, Aurer I, Nemet D, Zupancić-Salek S, Bogdanić V, Sertić D, Mrsić M, Pulanić R, Gasparović V, Labar B. Surgical resection in the treatment of primary gastrointestinal non-Hodgkin's lymphoma: retrospective study. *Croat Med J*. 2002; 43:555-60.
 72. Aurer I, Duraković N, Radman I, Nemet D, Zupancić-Salek S, Kovacević-Metelko J, Bogdanić V, Sertić D, Mrsić M, Mikulić M, Labar B. Combination of ifosfamide, methotrexate, and etoposide (IMVP) as a salvage therapy for relapsed and refractory aggressive non-Hodgkin lymphoma: retrospective study. *Croat Med J*. 2002; 43:550-4.

73. Sučić M, Zadro R, Burazer B, Labar B, Nemet D, Mrsić M, Aurer I, Mrsić S, Hitrec V, Boban D, Marković-Glamočak M, Batinić D, Užarević B, Stavljenić-Rukavina A. Acute promyelocytic leukemia M3: Cytomorphologic, immunophenotypic, cytogenetic, and molecular variants. *J Hematother Stem Cell Res*, 2002; 11:941-950.
74. Radman I, Bašić N, Labar B, Kovačević M, Metelko J, Aurer I, Bogdanić V, Zupančić-Šalek S, Nemet D, Jakić-Razumović J, Mrsić M, Šantek F, Grgić-Markulin LJ, Boban D. Long term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience). *Ann Oncol* 2002; 13:1650-55.
75. Suciú S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B, De Rosa G, Belhabri A, Giustolisi R, Delarue R, Liso V, Mirto S, Leone G, Bourhis JH, Fioritoni G, Jehn U, Amadori S, Fazi P, Hagemeijer A, Willemze R. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CRI): an intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial. *Blood* 2003; 102:1232-1240.
76. Oostervald M, Suciú S, Verhoef G, Labar B, Belhabri A, Aul C, Selleslag D, Ferrant A, Wijermans P, Mandelli F, Amadori S, Jehn U, Muus P, Zittoun R, Hess U, Anak O, Beeledens F, Willemze R, de Witte T. The presence of an HLA-identical sibling donor has no impact on outcome for patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of prospective study of EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). *Leukemia* 2003; 17:859-868.
77. Rozman P, Kara M, Kosir A, Labar B, Madrigal A, Middleton D, Navarrete C, Oudshoorn M, Schennach H, Vitek A, Bohinjec M. Are human platelet alloantigens (HPA) minor transplantation antigens in clinical bone marrow transplantation? *Bone Marrow Transplant* 2003; 31:497-506.
78. Mrsić M, Stavljenić-Rukavina A, Fumić K, Labar B, Bogdanić V, Potocki K, Kardum-Skelin I, Rovers D. Management of Gaucher disease in a post-communist transitional health care system: Croatian experience. *Croat Med J*. 2003; 44:606-9.
79. Gokbuget N, Bassan R, Dekker A, Dombret H, Foa R, Ifrah N, Kovacsovics T, Labar B, Mandelli F, Meloni G, Ribera JM, Smedmyr B, Vernant JP, Walewski J, Willemze R, Hoelzer D. Developing of European network for adult ALL. *Hematol J*. 2004; 5:46-52.
80. Labar B, Rudan I, Ivanković D, Biloglav Z, Mrsić M, Strnad M, Fucic A, Znaor A, Bradic T, Campbell H. Haematological malignancies in childhood in Croatia: Investigating the theories of depleted uranium, chemical plant damage and "population mixing". *Eur J Epidemiol* 2004; 19:55-60.
81. Golubić-Čepulić B, Budimir A, Plečko V, Plenković F, Mrsić M, Šarlija D, Vuk T, Skrlin J, Kalenić S, Labar B. *Morganella morganii* causing fatal sepsis in a platelet recipient and also isolated from a donor's stool. *Transf Med*. 2004; 14: 237-240.
82. Labar B, Suciú S, Zittoun R, Muus P, Marie JP, Fillet G, Peetermans M, Stryckmans P, Willemze R, Feremans W, Jaksic B, Bourhis JH, Burghouts JP, De Witte T for the EORTC Leukemia Group. Allogeneic stem cell transplantation in

- acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients ≤ 50 years old in first complete remission: results of the EORTC ALL-3 trial. *Haematologica*. 2004; 89: 809-817
83. Martinović S, Mazić S, Kisić V, Bašić N, Jakić-Razumović J, Borovečki F, Batinić D, Šimić P, Grgurević L, Labar B, Vukičević S. Expression of bone morphogenetic proteins in stromal cells from human bone marrow long-term culture. *J Histochem Cytochem*. 2004; 52:1159-1167.
 84. Huić D, Labar B, Huić M, Radman I, Dodig D, Mrsić M. Splenectomy? No, thank you! *Europ J Nucl Med Mol Imaging*. 2004; 31:1677-1677.
 85. Gratwohl A, Baldomero H, Labar B, Apperley J, Urbano-Ispizua A; Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT). Evolution of hematopoietic stem cell transplantation in Eastern and Western Europe from 1990 to 2003. A report from the EBMT activity survey. *Croat Med J*. 2004; 45:689-94.
 86. Aurer I, Radman I, Nemet D, Zupancić-Salek S, Bogdanić V, Mrsić M, Sertić D, Labar B. Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease. *Onkologie*. 2005 Nov;28:567-71.
 87. Grubić Z, Stingl K, Cecuk Jelčić E, Zunec R, Kastelan A, Serventi Seiwert R, Bogdanić V, Labar B, Kerhin Brkljčić V. Repetitive DNA polymorphisms in following chimerism after allogeneic bone marrow transplantation. *Clin Transplant*. 2005; 19:586-90.
 88. Grubić Z, Stingl K, Cecuk-Jelčić E, Zunec R, Serventi Seiwert R, Labar B, Rajić Lj, Brkljčić-Kerhin V. Evaluation of mixed chimerism in bone marrow transplantation program in Croatia. *Transplant Proc*. 2005; 37:1388-91.
 89. Golemović M, Sucić M, Zadro R, Mrsić S, Mikulić M, Labar B, Rajić LJ, Batinić D. IgH and TCRgamma gene rearrangements, cyclin A1 and HOXA9 gene expression in biphenotypic acute leukemias. *Leuk Res*. 2006; 30:211-21.
 90. Huić D, Mutvar A, Radman I, Grosev D, Labar B, Zuvčić M, Dodig D, Aurer I, Nemet D. The value of F-18 FDG triple-head coincidence PET in the posttreatment evaluation of patients with lymphoma. *Clin Nucl Med*. 2006; 31:275-8.
 91. Duletić-Nacinović A, Sever-Prebelić M, Stifter S, Jonjić N, Hasan M, Labar B. Interleukin-6 in patients with aggressive and indolent non-Hodgkin's lymphoma: a predictor of prognosis? *Clin Oncol (R Coll Radiol)*. 2006; 18:367-8.
 92. Čulić S, Labar B, Marušić A, Salamunić I. Correlations Among Age, Cytokines, Lymphocyte Subtypes, and Platelet Counts in Autoimmune Thrombocytopenic Purpura. *Pediatr Blood Cancer* 2006; 00:1-4
 93. Antica M, Dubravčić K, Weber I, Raic L, Labar B, Batinić D. A search for a mutation of the Aiolos phosphorylation domain in lymphocytes from patients with leukemia. *Haematologica*. 2007; 92:260-1.
 94. Aurer I, Lauc G, Dumić J, Rendić D, Matisić D, Milos M, Heffer-Lauc M, Flogel M, Labar B. Aberrant glycosylation of IgG heavy chain in multiple myeloma. *Coll Antropol*. 2007; 31:247-51.

95. Mitrović Z, Aurer I, Radman I, Ajduković R, Sertić J, Labar B. FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. *Haematologica*. 2007; 92:998-9.
96. Willemze R, Labar B. Post-remission treatment for adult patients with acute lymphoblastic leukemia in first remission: is there a role for autologous stem cell transplantation? *Semin Hematol*. 2007; 44:267-73.
97. Dumic M, Radman I, Krnic N, Nola M, Kusec R, Begovic D, Labar B, Rados M. Successful treatment of diffuse large B-cell non-hodgkin lymphoma with modified CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy and rituximab in a patient with Nijmegen syndrome. *Clin Lymphoma Myeloma*. 2007; 7:590-3.
98. Aurer I, Mitrović Z, Nemet D, Radman I, Sertić D, Serventi-Seiwerth R, Stern-Padovan R, Santek F, Nola M, Mrsić M, Labar B. Treatment of relapsed or refractory aggressive non-hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE. *J Chemother*. 2008; 20:640-4.
99. Mikulic M, Batinic D, Sucić M, Davidovic-Mrsic S, Dubravcic K, Nemet D, Serventi-Seiwerth R, Sertic D, Labar B. Biological features and outcome of biphenotypic acute leukemia: a case series. *Hematol Oncol Stem Cell Ther*. 2008; 1:225-30.
100. Vince A, Lepej SZ, Barsić B, Dusek D, Mitrović Z, Serventi-Seiwerth R, Labar B. LightCycler SeptiFast assay as a tool for the rapid diagnosis of sepsis in patients during antimicrobial therapy. *J Med Microbiol*. 2008; 57:1306-7.
101. Marković-Glamocak M, Sucić M, Ries S, Gjadrov-Kuvezdicić K, Labar B. Malignant epithelial tumors and hematologic malignancy. *Diagn Cytopathol*. 2008; 36:710-4.
102. Brcić I, Labar B, Perić-Balja M, Basić-Kinda S, Nola M. Terminal deoxynucleotidyl transferase negative T-cell lymphoblastic lymphoma in aleukemic patient. *Int J Hematol*. 2008; 88:189-91.
103. Bojanic I, Cepulic BG, Mazic S, Batinic D, Nemet D, Labar B. Toxicity related to autologous peripheral blood haematopoietic progenitor cell infusion is associated with number of granulocytes in graft, gender and diagnosis of multiple myeloma. *Vox Sang*. 2008;95:70-5.
104. Wachowiak J, labopin M, Miano M, Chybicka A, Stary J, Sterba J, Masszi T, labar B, Maschan A, Kowalczyk JR, Lange A, Holowiecki J, Kalman N, Afanassiev B, Dini G. haematopoietic stem cell transplantation in children in eastern European countries 1985-2004: development, recent activity and role of the EBMT/ESH Outreach Programme. *Bone Marrow Transplantation*. 2008; 41:112-117.
105. Mandelli F, Vignetti M, Sucić S, Stasi R, Petti MC, Meloni G, Muus P, Marmont F, Marie JP, Labar B, Thomas X, Di Raimondo F, Willemze R, Liso V, Ferrara F, Baila L, Fazi P, Zittoun R, Amadori S, de Witte T. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. *J Clin Oncol*. 2009; 27:5397-403.

106. Antolić MR, Zadro R, Sertić D, Labar B. Monitoring chronic myeloid leukemia patients responding to treatment with tyrosine kinase inhibitors by real-time quantitative polymerase chain reaction. *Biochemia Medica*. 2009; 19:63-72.
107. Ilić I, Mitrović Z, Aurer I, Basić-Kinda S, Radman I, Ajduković R, Labar B, Dotlić S, Nola M. Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab. *Int J Hematol*. 2009; 90:74-80.
108. Mitrović Z, Ilić I, Nola M, Aurer I, Sonicki Z, Basić-Kinda S, Radman I, Ajduković R, Labar B. CD43 expression is an adverse prognostic factor in diffuse large B-Cell lymphoma. *Clin Lymphoma Myeloma*. 2009; 9:133-7.
109. Salek SZ, Radman I, Pulanic D, Pasic A, Nola M, Labar B. Treatment of multiple relapsing non-melanoma skin cancers in a patient with severe hemophilia A. *Tumori*. 2009; 95:115-8.
110. Giebel S, Labopin M, Holowiecki J, Labar B, Komarnicki M, Koza V, Masszi T, Mistrik M, Lange A, Hellmann A, Vitek A, Pretnar J, Mayer J, Rzepecki P, Indrak K, Wiktor-Jedrzejczak W, Wojnar J, Krawczyk-Kulis M, Kyrzcz-Krzemien S, Rocha V. Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years. *Ann Hematol*. 2009; 88:1005-13.
111. Aljurf MD, Zaidi SZ, El Solh H, Hussain F, Ghavamzadeh A, Mahmoud HK, Shamsi T, Othman TB, Sarhan MM, Dennison D, Ibrahim A, Benchekroun S, Chaudhri N, Labar B, Horowitz M, Niederwieser D, Gratwohl A. Special issues related to hematopoietic SCT in the Eastern Mediterranean region and the first regional activity report. *Bone Marrow Transplant*. 2009;43:1-12.
112. Ludwig H, Hajek R, Tóthová E, Drach J, Adam Z, Labar B, Egyed M, Spicka I, Gisslinger H, Greil R, Kuhn I, Zojer N, Hinke A. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. *Blood*. 2009; 113:3435-42.
113. Huić D, Mutvar A, Kinda-Bašić S, Aurer I, Ciglar M, Grošev D, Radman I, Labar B. Negative predictive value of F-18-FDG coincidence PET in patients with Hodgkin's disease and a residual mass after therapy: a retrospective diagnostic test study. *Radiology and Oncology*. 2009;43:258-263.
114. Horvat I, Antolić MR, Zadro R, Sertić D, Labar B. Clinical significance of T315I ABL kinase domain mutation detection in patients resistant to imatinib mesylate therapy. *Biochemia Medica*. 2010; 20:75-81.
115. Vrbanus L, Sucić M, Marković-Glamocak M, Ries S, Gjadrov-Kuvezdíć K, Fabijanić I, Antulov J, Petrik J, Labar B. Apoptosis of leukemic cells: a case report. *Coll Antropol*. 2010; 34:705-11.
116. Raos M, Nemet D, Bojanić I, Sertić D, Batinić D, Dusak V, Dubravčić K, Mazić S, Serventi-Seiwerth R, Mrsić M, Golubić-Cepulić B, Labar B. Collection and composition of autologous peripheral blood stem cells graft in patients with acute myeloid leukemia: influence on hematopoietic recovery and outcome. *Coll Antropol*. 2010; 34:105-15.
117. Kuvezdíć KG, Aurer I, Ries S, Sucić M, Glamocak MM, Ilić I, Basić-Kinda S,

- Radman I, Labar B. FNA based diagnosis of head and neck nodal lymphoma. *Coll Antropol.* 2010; 34:7-12.
118. Labar B, Suciú S, Willemze R, Muus P, Marie JP, Fillet G, Berneman Z, Jaksic B, Feremans W, Bron D, Sinnige H, Mistrik M, Vreugdenhil G, De Bock R, Nemet D, Gilotay C, Amadori S, de Witte T; EORTC Leukemia Group. Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group. *Haematologica.* 2010; 95:1489-95.
 119. Ludwig H, Adam Z, Tóthová E, Hajek R, Labar B, Egyed M, Spicka I, Gisslinger H, Drach J, Kuhn I, Hinke A, Zojer N. Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. *Haematologica.* 2010; 95:1548-54.
 120. Durakovic N, Radojic V, Boban A, Mrcic M, Sertic D, Serventi-Seiwerth R, Nemet D, Labar B. Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant *Pseudomonas aeruginosa* in patients with hematologic malignancy: a matched pair analysis. *Intern Med.* 2011;50:1009-13.
 121. Hehlmann R, Grimwade D, Simonsson B, Apperley J, Baccarani M, Barbui T, Barosi G, Bassan R, Béné MC, Berger U, Büchner T, Burnett A, Cross NC, de Witte TJ, Döhner H, Dombret H, Einsele H, Engelich G, Foà R, Fonatsch C, Gökbuget N, Gluckman E, Gratwohl A, Guilhot F, Haferlach C, Haferlach T, Hallek M, Hasford J, Hochhaus A, Hoelzer D, Kiladjian JJ, Labar B, Ljungman P, Mansmann U, Niederwieser D, Ossenkoppele G, Ribera JM, Rieder H, Serve H, Schrotz-King P, Sanz MA, Saussele S; European LeukemiaNet. The European LeukemiaNet: achievements and perspectives. *Haematologica.* 2011; 96:156-62.
 122. Bojanic I, Dubravcic K, Batinic D, Cepulic BG, Mazic S, Hren D, Nemet D, Labar B. Large volume leukapheresis: Efficacy and safety of processing patient's total blood volume six times. *Transfus Apher Sci.* 2011; 44:139-47.
 123. Lübbert M, Suciú S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeyer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. *J Clin Oncol.* 2011; 29:1987-96.
 124. Mitrović Z, Ilić I, Aurer I, Kinda SB, Radman I, Dotlić S, Ajduković R, Labar B. Prognostic significance of survivin and caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP. *Pathol Oncol Res.* 2011; 17:243-7.
 125. Basak GW, Jaksic O, Koristek Z, Mikala G, Basic-Kinda S, Mayer J, Masszi T, Giebel S, Labar B, Wiktor-Jedrzejczak W; Central and Eastern European Leukaemia Group (CELG). Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. *Eur J Haematol.* 2011; 86:488-95.
 126. Basak GW, Mikala G, Koristek Z, Jaksic O, Basic-Kinda S, Cegledi A, Reti M,

- Masszi T, Mayer J, Giebel S, Hübel K, Labar B, Wiktor-Jedrzejczak W. Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late. *Leuk Lymphoma*. 2011; 52:1711-19.
127. Basak GW, Jaksic O, Koristek Z, Mikala G, Mayer J, Masszi T, Labar B, Wiktor-Jedrzejczak W; Central and Eastern European Leukemia Group (CELG). Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. *Am J Hematol*. 2011; 86:550-3.
128. Giles F, Mahon FX, Gjertsen B, Swords R, Labar B, Turkina A, Rosti G. Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. *Eur J Clin Invest*. 2012; 42:1016-26
129. Dujmovic D, Aurer I, Radman I, Serventi-Seiwerth R, Dotlic S, Stern-Padovan R, Dubravcic K, Santek F, Labar B. Addition of rituximab to high-dose methotrexate-based chemotherapy improves survival of adults with Burkitt lymphoma/leukemia. *Acta Haematol*. 2012;127:115-7.
130. Deschler B, Ihorst G, Platzbecker U, Germing U, März E, de Figuerido M, Fritzsche K, Haas P, Salih H, Giagounidis A, Selleslag D, Labar B, de Witte T, Wijermans P, Lübbert M. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. *Haematologica*. 2013; 98:208-16.
131. Gupta V, Richards S, Rowe J; Acute Leukemia Stem Cell Transplantation Trialists' Collaborative Group. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. *Blood*. 2013; 121:339-50.
132. Bojanic I, Serventi Seiwerth R, Golubic Cepulic B, Mazic S, Lukic M, Raos M, Plenkovic F, Golemovic M, Dubravcic K, Perkovic S, Batinic D, Labar B. Treatment of chronic GVHD with extracorporeal photochemotherapy. *Transfus Apher Sci*. 2013; 48:193-4.
133. Willemze R, Suciú S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P, Mistrik M, Amadori S, Specchia G, Fabbiano F, Nobile F, Sborgia M, Camera A, Selleslag DL, Lefrère F Sr, Magro D, Sica S, Cantore N, Beksac M, Berneman Z, Thomas X, Melillo L, Guimaraes JE, Leoni P, Luppi M, Mitra ME, Bron D, Fillet G, Marijt EW, Venditti A, Hagemeijer A, Mancini M, Jansen J, Cilloni D, Meert L, Fazi P, Vignetti M, Trisolini SM, Mandelli F, de Witte T. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. *J Clin Oncol*. 2014; 32:219-28.
134. Valković T, Seili-Bekafigo I, Bašić-Kinda S, Labar B, Duletić-Načinović A, Pećanić S, Jonjić N. Therapy-related acute myeloblastic leukemia after splenectomy in a patient with composite lymphoma developing after treatment of chronic lymphocytic leukemia. *Ann Hematol*. 2014; 93:1057-9.
135. Aslanyan MG, Kroeze LI, Langemeijer SM, Koorenhof-Scheele TN, Massop M, van Hoogen P, Stevens-Linders E, van de Locht LT, Tönnissen E, van der Heijden A, da Silva-Coelho P, Cilloni D, Saglio G, Marie JP, Tang R, Labar B, Amadori S, Muus P, Willemze R, Marijt EW, de Witte T, van der Reijden BA, Suciú S, Jansen JH.

- Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial. *Ann Hematol.* 2014; 93:1401-12.
136. Oosterveld M, Suciú S, Muus P, Germing U, Delforge M, Belhabri A, Aul C, Selleslag D, Ferrant A, Marie JP, Amadori S, Jehn U, Mandelli F, Hess U, Hellström-Lindberg E, Cakmak-Wollgast S, Vignetti M, Labar B, Willemze R, de Witte T. Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies. *Ann Hematol.* 2015; 94:23-34.
137. Hengeveld M, Suciú S, Chelgoum Y, Marie JP, Muus P, Lefrère F, Mandelli F, Pane F, Amadori S, Fioritoni G, Labar B, Baron F, Cermak J, Bourhis JH, Storti G, Fazi P, Hagemeijer A, Vignetti M, Willemze R, de Witte T. High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT. *Bone Marrow Transplant.* 2015; 50:341-7.
138. Becker H, Suciú S, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger KH, Hagemeijer A, Schaefer HE, Fiaccadori V, Baron F, Ganser A, Aul C, de Witte T, Wijermans PW, Lübbert M. Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG). *Ann Hematol.* 2015. [Epub ahead of print]

b) radovi objavljeni u domaćim časopisima koji su s predhodnim izjednačeni

1. Labar B.: Prikaz dvojice bolesnika s obiteljskom, kroničnom, intermitentnom, indirektnom bilirubinemijom tipa Gillberth. *Liječ Vjesn.* 1974; 96:164-166.
2. Mihelčić R., Labar B.: Prikaz bolesnika sa primarnom hemoragičnom trombocitemijom. *Bilt Hemat Transf.* 1975; 3:41-47.
3. Labar B., Nazor A., Reiner Ž., Polovina J., Popijač S.: Enzimi u eritrocitu bolesnika s indirektnom hiperbilirubinemijom. *Liječ Vjesn.* 1978; 100:615-617.
4. Labar B., Jakšić B., Nazor A.: Acquired red cell pyruvate kinase deficiency in acute leukemias, *Haematologica.* 1978; 63:555-560.
5. Labar B., Nazor A., Reiner Ž., Popijač S., Polovina J.: Enzimi u eritrocitu bolesnika s hemolizom. *Liječ Vjesn.* 1979; 101:101-104.
6. Labar B., Stanulović M., Jerenče D.: Nasljedna hemolitička anemija zbog deficita enzima piruvat kinaze u eritrocitu. *Liječ Vjesn.* 1979; 101:557-559.
7. Labar B., Stanulović M., Jerenče D.: Nasljedna hemolitička anemija zbog deficita enzima glukoza-6-fosfat dehidrogenaze u eritrocitu. *Liječ Vjesn.* 1979; 101:560-562.

8. Labar B.: Transplantacija koštane moždine. *Lij vjes*, 102:192-194, 1980.
9. Miko M., Labar B., Čepelja Z., Hegedušić Lj., Vrbanec Z.: Feltyjev sindrom. *Reumatizam*. 1980; 27:5-10, 1980.
10. Labar B., Bogdanić V., Kaštelan A., Grgičević D., Vrtar M., Krajina Z., Kamauf-Balabanić B., Kerhin-Brkljačić V., Francetić I., Zimonja-Krišković J.: Transplantacija koštane srži u liječenju teške aplastične anemije. *Liječ Vjesn*. 1984; 106:219-223.
11. Labar B., Stavljenić A., Jusufhodžić L.: Metabolizam u eritrocitu bolesnika s akutnom leukemijom i deficitom enzima piruvat kinaze. *Liječ Vjesn*. 1984; 106:447-451.
12. Bogdanić V., Dobrić I., Labar B.: Reakcija transplantata protiv primaoca kao komplikacija transplantacije koštane srži. *Liječ Vjesn*. 1984; 106:238-240.
13. Kaštelan A., Kaštelan M., Labar B.: Izbor davaoca za transplantaciju koštane srži. *Liječ Vjes*. 1984; 106:241-245.
14. Grgičević D., Labar B., Bogdanić V., Kerhin-Brkljačić V., Kaštelan A.: Transfuziološko liječenje bolesnika s teškom aplastičnom anemijom nakon transplantacije koštane srži. *Liječ Vjesn*. 1985; 107:85-89.
15. Labar B., Jusufhodžić L.: Utjecaj citostatske terapije na aktivnost enzima piruvat kinaze u eritrocitu bolesnika s akutnom mijeloičnom leukemijom. *Liječ Vjesn*. 1985; 107:61-63.
16. Francetić I., Kamauf-Balabanić B., Labar B., Bogdanić V.: Profilaktička primjena antimikrobnih lijekova u bolesnika liječenih transplantacijom koštane srži. *Liječ Vjesn*. 1985; 107:125-127.
17. Labar B., Bogdanić V., Nemet D., Kaštelan A., Pavletić Ž., Mrić M., Vrtar M., Dobrić I., Brkljačić V., Markulin-Grgić Lj., Francetić I., Boban D., Marušić M.: Transplantacija koštane srži. *Liječ Vjesn*. 1987; 109:449-452.
18. Labar B.: Transplantacija koštane srži - dosadašnja iskustva i perspektive. *Bilten Hemat Transf*. 1987; 15:3-26.
19. Aurer I., Kolevska T., Labar B., Kračun I., Nemet D., Marušić M., Bogdanić V.: Kultura koštane srži u bolesnika s akutnom mijeloičnom leukemijom. *Liječ Vjesn*. 1988; 110:405-409.
20. Pavletić Ž., Labar B., Čepelja Z., Mrić M., Kovačević-Metelko J., Bogdanić V., Nemet D.: Agranulocitoza - učestalost i kliničko značenje (prikaz 37 vlastitih slučajeva). *Liječ Vjesn*. 1988; 110:413-416.
21. Dobrić I., Vujašinović S., Kaštelan A., Baričević B., Labar B., Bogdanić V., Nemet D.: Promjene u koži uslijed reakcije transplantata protiv primaoca. 1. Patogeneza i dijagnostika. *Liječ Vjesn*. 1989; 110:436-438.
22. Dobrić I., Vujašinović S., Labar B., Bogdanić V., Nemet D., Kaštelan A., Baričević B., Vranešić Č., Škrinjar Lj.: Promjene u koži uslijed reakcije transplantata protiv primaoca. 2. Vlastita klinička opažanja te svjetlosnomikroskopski i elektronskomikroskopski nalazi. *Liječ Vjesn*. 1989; 111:76-80.
23. Nemet D., Labar B., Bogdanić V., Kolevska T., Mrić M., Pavletić Ž., Kalenić S., Vrtar M., Marušić M., Markulin-Grgić Lj., Boban D., Francetić I.: Liječenje neoplastičnih hematoloških bolesti intenzivnom radiokemoterapijom

- i transplantacijom krioprezervirane koštane srži. *Liječ Vjesn.* 1989; 111:348-353.
24. Aurer I., Labar B.: Onkogeni u akutnim mijeloičnim leukemijama. *Liječ Vjesn.* 1989; 111:474-478.
 25. Jurašinović Ž., Aralica M., Kalany J., Poropat M., Dodig D., Labar B.: Naša iskustva u dijagnostici tumora pomoću ⁶⁷Ga-citrata. *Radiol Jugosl.* 1990; 24:159-161.
 26. Minigo H., Nemet D., Planinc-Peraica A., Bogdanić V., Labar B., Jakšić B., Hauptman E.: High dose Ara-C as induction therapy of acute myeloid leukaemia. *Folia Haematologica*, 117:135-140, 1990
 27. Pavletić Z, Labar B. Hematopoetski faktori rasta. *Liječ Vjesn.* 1990; 112:339-46.
 28. Radman I, Kalenić S, Stoiljković I, Perković D, Labar B. Sepsis caused by *Yersinia enterocolitica* in a female patient with liver cirrhosis. *Liječ Vjesn.* 1991; 113:34-6.
 29. Pavletić Ž. Labar B., Marušić M., Bogdanić V., Nemet D., Mrsić M., Petrovečki M., Užarević B., Marković J., Matek Z.: Imunološki oporavak nakon transplantacije koštane srži. *Libri Oncol.* 1991; 2:9-19, 1991.
 30. Jakić-Razumović J, Labar B, Cör A, Radman I. The nucleolar organizer region in malignant non-Hodgkin's lymphoma. *Liječ Vjesn.* 1992;114(1-4):18-21.
 31. Labar B.: Immune antileukemia effect as a model for immunotherapy in leukemia. *Croat Med J.* 1993; 34:194-196.
 32. Serventi-Seiwerth R, Radman I, Zupančić-Šalek S, Jakić-Razumović J, Labar B.: Hypereosinophilia in patients with malignant tumors. *Libri Oncol.* 1993; 22:143-147, 1993.
 33. Labar B. Blood cell transplantation, current status, future trends, *Libri Oncol* 1995; 24:53-59.
 34. Baričević B, Dobrić I, Poje G, Marinović B, Labar B, Bogdanić V. Graft versus host disease diagnosed in a five years period (1988-1993): Histopathological grading and relation to time of appearance and skin site. *Acta Dermatovenorol Croat.* 1995; 3:11-16.
 35. Labar B, Mrsić M, Nemet D, Francetić I, Bogdanić V, Radman I, Maravić N.: Ondansetron for prophylaxis of nausea and vomiting after bone marrow transplantation. *Libri Oncol.* 1995; 3:131-135.
 36. Nemet D, Labar B, Grahovac B, Mrsić M, Radman I, Bogdanić V, Hitrec V, Zaher D, Sertić D, Aurer I, Bošnjak A, Boban D. All-trans retinoic acid as remission induction therapy for acute promyelocytic leukemia and detection of residual disease in remission by reverse transcription polymerase chain reaction assay, *Croat Med J* 1995; 36: 93-98.
 37. Labar B. Anaemia, *Croat Sports Med J*, 1995; 10:65-71.
 38. Labar B, Mrsić M, Nemet D, Bogdanić V, Kalenić S, Kaštelan A, Radman I, Aurer I, Boban D, Batinić D, Rajić Lj, Grgić-Markulin Lj, Francetić I, Zupančić-Šalek S, Kovačević J, Sertić D, Herljević Z. Age as a prognostic Factor following Stem Cell Transplantation in Acute Leukemia. *Croatian Med J* 1997, 38:332-337.

39. Stanović Janda S, Boranić M, Skodlar J, Petrovečki M, Nemet D, Labar B. Effect of opioid peptide methionine-enkephalin in long-term cultures of human bone marrow. *Acta med Croatica* 2000;53:99-105.
- Gjadrov Kuveždić K, Sučić M, Boban D, Marković Glamločak M, Ries S, Stavljenić Rukavina A, Labar B. PCR in situ u dijagnostici akutnih leukemija. *Liječ Vjesn.* 2000; 122:222-225.
40. Bašić-Jukić N, Kes P, Labar B. Myeloma Kidney: Pathogenesis and Treatment, *Acta Med Croat*, 2001; 55:169-175.
41. Bašić-Jukić N, Bašić-Koretić M, Radman I, Labar B. Reed-Sternberg cells in the pathogenesis of Hodgkin's disease. *Acta Med Croatica.* 2001; 55:115-21.
42. Bašić-Kes V, Bašić-Jukić N, Kes P, Demarin V, Labar B. Neurologic sequelae of bone changes in multiple myeloma and its therapy, *Acta Med Croat*, 2002; 56:103-7.
43. Bulum J, Labar B, Mikulić M, Bogdanić V, Sertić D, Nemet D, Krečak-Gverić V, Kovačević J, Serventi-Seiwerth R, Mrsić Davidović S, Zadro R, Boban D. Liječenje kronične mijeloične leukemije u uznapredovaloj fazi bolesti imatinibom. *Liječ Vjesn.* 2003;125:176-179.
44. Bašić-Jukić N, Labar B. Immunosuppressive drugs in the prevention and treatment of GVHD after allogenic bone marrow transplantation. *Acta Med Croatica.* 2003; 57:131-9.
45. Bulum J, Labar B, Mikulić M, Bogdanić V, Sertić D, Nemet D, Krečak-Gverić V, Kovačević J, Serventi-Seiwerth R, Mrsić-Davidović S, Zadro R, Boban D. Treatment of chronic myeloid leukemia with imatinib in the accelerated stage of the disease. *Lijec Vjesn.* 2003; 125:176-9.
46. Mrsić M, Stavljenić-Rukavina A, Fumić K, Labar B, Bogdanić V, Potocki K, Kardum-Skelin I, Rovers D. Management of Gaucher disease in a post-communist transitional health care system: Croatian experience. *Croat Med J.* 2003; 44:606-9.
47. Zupanić-Krmek D, Nemet D, Mrsić M, Bogdanić V, Labar B, Jandrić M, Kalenić S. Risk factors for invasive fungal infections during intensive chemotherapy of acute leukemia--retrospective study. *Acta Med Croatica.* 2004; 58:275-84.
48. Aurer I, Mitrović Z, Radman I, Kovacević-Metelko J, Nemet D, Serventi-Seiwerth R, Stern-Padovan R, Jakic-Razumović J, Nola M, Zupancić-Salek S, Sertić D, Labar B. Rituximab in the treatment of indolent non-Hodgkin's lymphoma. *Lijec Vjesn.* 2004; 126:307-11.
49. Bojanić I, Golubić Cepulić B, Nemet D, Rajić L, Batinić D, Labar B. Characteristics of autologous peripheral blood stem cells in pediatric patients. *Lijec Vjesn.* 2006; 128:43-8.
50. Aurer I, Huić D, Žuvić M, Sever-Prebelić M, Ajduković R, Radman I, Škare-Librenjak Lj, Ostojić-Kolonić S, Labar B. ⁹⁰Y-ibritumomab tiuksetan u bolesnika s refraktornim folikularnim limfomom ili u relapsu nakon rituksimaba. *Liječ Vjesn* 2006; 128:224-227.
51. Aurer I, Mitrović Z, Kovacević-Metelko J, Radman I, Bašić-Kinda S, Gjadrov-Kuveždić K, Jakić-Razumović J, Dubravčić K, Ries S, Nola M, Zupancić-

- Salek S, Labar B. Treatment of hairy cell leukemia with cladribine. *Lijec Vjesn.* 2007; 129:80-3.
52. Mitrović Z, Radman I, Aurer I, Petranović D, Santek F, Labar B. Primary central nervous system lymphoma--a single center experience. *Lijec Vjesn.* 2007; 129:391-5.
 53. Golubić Cepulić B, Bojanić I, Batinić D, Nemet D, Labar B. Hematopoietic stem cell bank at Zagreb University Hospital Center, Zagreb, Croatia. *Acta Med Croatica.* 2007; 61:505-9.
 54. Brkljacić-Kerhin V, Cecuk-Jelčić E, Grubić Z, Stingl K, Labar B. Registry of cell and tissue donors. *Acta Med Croatica.* 2007; 61:463-6.
 55. Boban A, Sertić D, Radman I, Zupancić-Salek S, Zadro R, Labar B. Anagrelide for treatment of patients with essential thrombocythaemia. *Lijec Vjesn.* 2008; 130:141-5.
 56. Batinić D, Dubravčić K, Rajić L, Mikulić M, Labar B. Biphenotypic and bilineal acute leukemias. *Acta Med Croatica.* 2008; 62:387-90.
 57. Labar B, Nemet D, Sucić M, Batinić D, Zadro R, Mrsić S, Serventi-Seiwerth R, Sertić D, Mikulić M, Duraković N. Current approach to diagnosis and treatment of acute leukemia in adults. *Acta Med Croatica.* 2008; 62:403-8.
 58. Sucić M, Batinić D, Zadro R, Mrsić S, Labar B. Cytomorphology of acute mixed leukemia. *Acta Med Croatica.* 2008; 62:379-85.
 59. Pulanić D, Šalek SZ, Labar B. Thrombophilia--inherited and acquired susceptibility to thrombosis. *Lijec Vjesn.* 2009; 131:236-7.
 60. Cecuk-Jelčić E, Kerhin-Brkljacić V, Grubić Z, Labar B. World's registry of bone marrow donors. *Acta Med Croatica.* 2009; 63:251-3.
 61. Labar B. Plasticity of hematopoietic stem cells. *Acta Med Croatica.* 2009; 63:227-30.
 62. Mrsić M, Seiwerth RS, Labar B, Bogdanić V, Nemet D, Duraković N, Mikulić M, Sertić D, Aurer I, Radman I, Zupancić-Salek S. Twenty years of severe aplastic anemia treatment at Department of Hematology, University Department of Medicine, Zagreb University Hospital Center, Zagreb, Croatia. *Acta Med Croatica.* 2009; 3:209-14.
 63. Seiwerth RS, Mrsić M, Nemet D, Bogdanić V, Mikulić M, Sertić D, Grković L, Cecuk E, Bojanić I, Batinić D, Labar B. Treatment of acute leukemia with allogeneic stem cell transplantation. *Acta Med Croatica.* 2009; 63:205-8.
 64. Labar B, Kusec R, Jaksić B, Skare-Librenjak L, Nacinović-Duletić A, Petricević-Sincić J, Carzavec D, Coha B, Gverić-Krecak V, Corović E, Lang N, Lojen-Nemet Z, Babok-Flegarić R; Croatian Cooperative Group for hematologic disorders. Diagnosis and therapy for patients with essential thrombocythemia. Guidelines of Croatian Cooperative Group for hematologic disorders--KROHEM. *Lijec Vjesn.* 2010; 132:333-9.
 65. Beader N, Kalenić S, Labar B. Diagnostic approach and therapy for cytomegalovirus (CMV) infection following allogeneic stem cell transplantation. *Lijec Vjesn.* 2011; 133:389-96.
 66. Stingl K, Zunec R, Serventi-Seiwerth R, Labar B, Grubić Z. The influence of tumor necrosis factor microsatellite polymorphisms on patient survival following hematopoietic stem cell transplantation. *Croat Med J.* 2012; 53:24-9.

67. Bojanić I, Seiwerth RS, Mazić S, Dubravčić K, Batinić D, Cepulić BG, Labar B. Extracorporeal photopheresis in treatment of chronic graft versus host disease. *Lijec Vjesn.* 2013; 135:139-44.

A2 KNJIGE

1. Autor:

- Labar B. Športska medicina, monografija 1999.

2. Koautor poglavlja u knjigama i udžbenicima:

- a) B Labar: Transplantacija koštane srži, u Dekaris D, Čulo F. i suradnici *Klinička imunologija u nas*, Naprijed, 1990, str. 515-532.
- b) Strozzi M, Zupančić-Šalek S, Labar B: Promjene kardiovaskularnog sustava u hematoloških bolesnika, Čustović F, Goldner V, Čikeš I. i suradnici *Klinička kardiologija*, Medicinska naklada, 1995. str 673-682.
- c) Labar B. Zloćudna preobrazba stanica mijelopojeze i limfopojeze, u Gamulin S, Marušić M, Krvavica S. i suradnici *Patofiziologija*, 1995 i 2002, . Str. 547-551.
- d) Labar B: Leukemije, u Turić M, Kolarić K, Eljuga D. *Klinička onkologija*, Globus, 1996, str. 743-777.
- e) Labar B. Kožne promjene kod reakcije transplantata protiv primatelja, u Lipozenčić J i sur. *Dermatovenerologija*, Naklada Zadro, 1999. str 200-204.
- f) Labar B: Imunoterapija – biološko liječenje solidnih tumora, u Mršić-Krmpotić Z, Roth A i sur. *Internistička onkologija*, Medicinska naklada 2004, str. 69-80.
- g) Labar B: Bolesti krvotvornog sustava, u Šimunić V. i sur. *Reprodukcijnska endokrinologija i neplodnost*, Školska knjiga, 2012 str. 345-357.

3. Urednik

- Jakšić B, Labar B, Grgičević D i suradnici: *Hematologija i transfuziologija*, Jumena 1989.
- Vrhovac B. uz urednički odbor (Bakran I, Granić M, Jakšić B, Labar B, Vucelić B.) *Interna medicina*, Naprijed 1991. 1997, 2003.
- Labar B., Hauptmann E. i suradnici: *Hematologija*, Školska knjiga 1998. 2003, 2007.,
- Čepelak I, Štraus B, Dodig S, Labar B. *Medicinsko-biokemijske smjernice*, Medicinska naklada, 2004.
- Labar B i sur. *Hematologija*, Školska knjiga 2015. u tisku

A3 MONOGRAFIJE

Radovi objavljeni u Monografijama:

1. Bogdanić V, Labar B., Mrić M., Nemet D., Serventi-Seiwerth R.: Low dose Ara-C in the treatment of myelodysplastic syndromes. *Bone Marrow Transplantation*. 4(Suppl.3):26-27, 1989.
5. Zupančić-Šalek S, Aurer I, Bogdanić V, Nemet D, Mrić M, Labar B. Donor characteristics in allogeneic bone marrow transplantation . *Bone Marrow Transplant* 1989; 4(Suppl 3):107.
6. Gašparović V, Labar B, Puljević D, Skodlar J, Bogdanić V, Ivanović D, Gjurašin M. Elimination of antibodies by plasma exchange in ABO incompatible bone marrow transplantation. *Bone Marrow Transplant* 1989; 4(Suppl 3):109.
8. Pavletić Ž, Petrovečki M, Bogdanić V, Nemet D, Užarević B, Matek Z, Marković J, Marušić M, Labar B. The significance of immunologic monitoring after allogeneic bone marrow transplantation. *Bone Marrow Transplantation*, 1989; 4(Suppl. 3.):111.
9. de Witte T, Suciū S, Verhoef G, Labar B, Archimbaud E, Aul C, Selleslag D, Ferrant A, Wijermans P, Mandelli F, Amadoris S, Jehn U, Muus P, Demuyneck H, Dardenne M, Zittoun R, Willemze R, Gratwohl A, Apperley J. Intensive chemotherapy followed by stem cell transplantation for the treatment of myelodysplastic syndromes. *Acute leukemia VIII: Prognostic factors and Treatment Strategies*, 2001:649-654.
10. Labar B. Acute myeloid leukemia. *Liječ Vjesn.* 2011; 133(suppl 4):72-74.
11. Labar B. Allogeneic Stem cell transplantation for hematological malignancies – current approach and future trends. *Liječ Vjesn.* 2011; 133(suppl 4):75-78.
12. Labar B, Wierzbowska A, Mihaylov G, Moicean A, Tomić D, Borbenyi Z, Ondrak K, Cevreska L, Mistrik M, Knopinska-Poslužny W, Bijedić V. Diagnostic and Treatment Approach for Acute Myeloblastic Leukemia – report from central and Eastern European Leukemia Group (CELG). *Liječ Vjesn.* 2011; 133(suppl 4):81-85.

A4 RADOVI U ZBORNICIMA

a) Na međunarodnim skupovima

1. Labar B., Čvorišćec D., Bogdanić V., Stavljenić A., Plavšić F.: Predictive value of urinary enzymes and Tamm-Horsfall protein as indices for nephrotoxicity in patients treated with bone marrow transplantation. Abstract, *J Cell Biochem*, Suppl. 10D, 1986, p. 231, UCLA Symposia on Molecular & Cellular Biology, March 30 - April 5, 1986. Keyston, USA.
2. Labar B., Bogdanić V., Nemet D., Pavletić Z., Mrić M., Kaštelan A., Vrtar M., Grgić-Markulin Lj., Dobrić I.: Bone marrow transplantation for leukemia in Zagreb, Yugoslavia. Abstract, *J Cell Biochem*, Suppl. 12C, 1988, p. 91. UCLA Symposia on Molecular and Cellular Biology, March 6-12, 1988 Tammaron, USA.

3. Bogdanić V, Mrišić M, Nemet D, Plavšić F, Pavletić Ž, Labar B. Cyclosporine and methotrexate versus cyclosporine alone for prevention of acute graft versus host disease after bone marrow transplantation for leukaemia. Abstract. *J. Cell Biochemistry, Suppl. 12C*, 1988, p. 104. UCLA Symposia on Molecular and Cellular Biology, March 6-12, 1988, Tammaron USA.
4. Bogdanić V, Nemet D, Labar B, Vrtar M, Kaštelan A, Presečki V, Mrišić M, Radman I, Pavletić Ž. Low incidence of interstitial pneumonitis after bone marrow transplantation : Assessment of risk factors. *Leukaemia 1988. First Advanced International course, Genoa, November 5-8, 1988. Abstract str 249, Haematologica 1988, 73(5)(suppl):N5.*
5. Labar B, Bogdanić V, Nemet D, Vrtar M, Mrišić M. Total body irradiation with or without lung shielding for allogeneic bone marrow transplantation. Abstract, *Experimental Hematology 1989;17(6):544*, Proceedings of the XVIII th Annual Meeting of International Society for Experimental Hematology, Paris 16-20 July, 1989.
6. Batinić D, Kolevska T, Užarević B, Bogdanić V, Nemet D, Labar B, Marušić M. The influence of harvesting procedure on cell subsets composition and clonogenic potential of human bone marrow transplants. Abstract, *Experimental Hematology 1989;17(6):549*, Proceedings of the XVIII th Annual Meeting of International Society for Experimental Hematology, Paris 16-20 July, 1989.
7. Batinić D., Tindle R., Boranić M., Boban D., Marković M., Sučić M., Užarević B., Labar B., Marušić M., Rajić Lj.: Expression of hemopoietic progenitor cell-associated antigen BI-3C5/CD34 in leukemia, Abstract, *Experimental Hematology 1989;17(6):561*, Proceedings of the XVIII th Annual Meeting of International Society for Experimental Hematology, Paris 16-20 July, 1989.
8. Kolevska T, Nemet D, Labar B, Marušić M. Clonogenic potential of unseparated normal bone marrow: Influence of short-term storage regimen. Abstract, *Experimental Hematology 1989;17(6):719*, Proceedings of the XVIII th Annual Meeting of International Society for Experimental Hematology, Paris 16-20 July, 1989.
9. Gerhartz HH, Visani G, Delmer A, Zwierzina H, Ribeiro M, Jacobs A, Marcus R, Baumelou M, Fiere D, Labar B, Sizoo W, Efra A, Peetermans M, Davis HP, Stern AC, Solbu G, Sociu S, de Witte T, Zittoun R.: Randomized phase II study with GM-CSF and low-dose ARA-C in patients with "high risk" myelodysplastic syndromes (MDS), Abstract, *Blood suppl.1119a*, Thirty-first Annual Meeting of the American Society of Hematology, December 1-5, 1989. Atlanta, USA.
10. Labar B, Bogdanić V, Nemet D, Vrtar M, Mrišić M. Total body irradiation with or without lung shielding for allogeneic bone marrow transplantation. Abstract, *Bone Marrow Transplantation 1990;5(Suppl 2):126*. Sixteenth Annual Meeting of the European Cooperative Group for Bone Marrow Transplantation, The Hague, The Netherlands, 1990.
11. Grahovac B, Labar B, Stavljenić A, Bogdanić V, Nemet D. Isoenzymes as genetic markers in allogeneic bone marrow transplantation. Abstract, *Bone Marrow Transplantation 1990;5(Suppl 2):130*. Sixteenth Annual Meeting of the European Cooperative Group for Bone Marrow Transplantation, The Hague, The Netherlands, 1990.

12. Labar B, Pavletić Ž, Bogdanić V, Nemet D, Aurer I, Jakić J.: Prostaglandin E2 for prevention of oral mucositis in patients with leukemia undergoing bone marrow transplantation: a randomized double-blind clinical trial. Abstract, *Exp Hematol*, 18:700, XIXth Annual Meeting of International Society for Experimental Hematology, August 26-30, 1990, Seattle, USA.
13. Mrić M, Labar B, Bogdanić V, Nemet D, Radman I. Chemotherapy versus bone marrow transplantation in adults with acute lymphoblastic leukemia. Abstract. *Exp Haematology* 1991;19(6):575. XXth Annual Meeting of the International Society for Experimental Hematology, 1991, Parma, Italy.
14. 21. Labar B, Mrić M, Bogdanić V, Nemet D, Radman I. Chemotherapy versus bone marrow transplantation in adults with acute myelogenous leukemia. Abstract, *Exp Haematology* 1991;19(6):575. XXth Annual Meeting of the International Society for Experimental Hematology, 1991, Parma, Italy.
15. Jakic-Razumovic J, Labar B, Cor A, Radman I: Nucleolar organizer regions in malignant non-Hodgkin's Lymphomas. Abstract, *Pathology Research and Practice* 187:701, XIIIth European Congress of Pathology, Septembar 1-6, 1991, Ljubljana, Yugoslavia.
16. Radman I., Kovacevic J., Bogdanic V., Nemet D., Zupancic-Salek S., Jakic J., Labar B.: Systemic chemotherapy of cutaneous lymphomas, Abstract, *Europ J Cancer*, Suppl 2:S246, Sixth European Conference on Clinical Oncology and Cancer Nursing, 1991, Firenze, Italy.
17. Radman I, Kovačević J, Bogdanić V, Nemet D, Zupančić-Šalek S, Jakić J, Labar B. Systemic chemotherapy of cutaneous lymphomas, Abstract, *Europ J Cancer* 1991; Suppl 2 : S246. Sixth European Conference on Clinical Oncology and Cancer Nursing, 1991, Firenze, Italy.
18. Labar B, Mrić M, Nemet D, Bogdanić V, Radman I, Zupančić - Šalek S, Kovačević - Metelko J, Aurer I: Comparison of chemotherapy versus allogeneic bone marrow transplantation in adults with acute myelogenous leukaemia, Abstract, Annual Congress of the Austrian Society of Haematology and the Hungarian Societes of Hematology and Oncology, Graz, 27-30 September 1992, *Annals of Hematology* 1992; 65 (Suppl): A11.
19. Radman I, Kovačević - Metelko J, Labar B, Bogdanić V, Nemet D, Zupančić - Šalek S, Mrić M, Jakić - Razumović J: Is combined modality treatment superior to radiotherapy alone for CS IA-IIB Hodgkin's disease, Abstract, *Ibidem*, Annual Congress of the Austrian Society of Haematology and the Hungarian Societes of Hematology and Oncology, Graz, 27-30 September 1992, *Annals of Hematology* 1992; 65 (Suppl): A21.
20. Radman I, Kovačević - Metelko J, Bogdanić V, Nemet D, Zupančić - Šalek S, Mrić M, Jakić - Razumović J, Labar B: Systemic chemotherapy of cutaneous lymphomas. Abstract Annual Congress of the Austrian Society of Haematology and the Hungarian Societes of Hematology and Oncology, Graz, 27-30 September 1992, *Annals of Hematology* 1992; 65 (Suppl): A21.
21. Mrić M, Nemet D, Labar B, Bogdanić V, Radman I, Zupančić - Šalek S, Kovačević - Metelko J, Aurer I.: Chemotherapy versus allogeneic bone marrow transplantation in adults with acute lymphoblastic leukaemia, Abstract, Annual Congress of the Austrian Society of Haematology and the Hungarian Societes of Hematology and

- Oncology, Graz, 27-30 September 1992, *Annals of Hematology* 1992; 65 (Suppl): A 24.
22. Mrsić M, Labar B, Bogdanić V, Nemet D, Dobrić I, Jakić - Razumović J. Combination of cyclosporine and methotrexate for GVHD prophylaxis: Long term follow-up. Abstract, Annual Congress of the Austrian Society of Haematology and the Hungarian Societies of Hematology and Oncology, Graz, 27-30 September 1992, *Annals of Hematology* 1992; 65 (Suppl): A24.
 23. Labar B, Bogdanić V, Nemet D, Mrić M, Sertić D, Radman I, Aurer I, Maravić N, Šneller V, Zupančić-Šalek S. Bone marrow transplantation or immunosuppressive therapy for the treatment of severe aplastic anemia, American Society of Hematology, Thirty-Fifth Annual Meeting, 1993, St. Luis, Mo, USA, *Blood* 1993, 82 (Suppl 1), Abstract No 353.
 24. Nemet D, Maravić N, Tomašković M, Labar B, Bogdanić V, Mrić M, Dobrić I, Skerlev M, Šneller V. Cyclosporin A induced graft-versus-host disease after autologous bone marrow transplantation, 20th Annual Meeting of the European Group for Bone Marrow Transplantation, Harrogate, UK, 13-17 March, 1994, *Bone Marrow Transplantation*, Abstract No. 265.
 25. Bogdanić V, Labar B, Nemet D, Mrić M, Kovačević-Metelko J, Radman I, Zupančić-Šalek S, Aurer I, Maravić N, Šneller V. Bone marrow transplantation for chronic myelogenous leukaemia in 1st chronic phase - Zagreb experience. 20th Annual Meeting of the European Group for Bone Marrow Transplantation, Harrogate, UK, 13-17 March, 1994, *Bone Marrow Transplantation*, Abstract No. 29.
 26. Labar B, Mrić M, Bogdanić V, Nemet D, Maravić N, Šneller V. Ondasetron, 5-HT₃ receptor antagonist in prophylaxis of nausea and vomiting after BMT. 20th Annual Meeting of the European Group for Bone Marrow Transplantation, Harrogate, UK, 13-17 March, 1994, *Bone Marrow Transplantation*, Abstract No. 383.
 27. Batinić D, Šneller V, Nemet D, Užarević B, Rudolf M, Petrovečki M, Peter B, Kuvačić I, Mrić M, Maravić N, Marušić M, Labar B. Immunophenotype, proliferative response and CFU-GM content of human umbilical cord blood. 20th Annual Meeting of the European Group for Bone Marrow Transplantation, Harrogate, UK, 13-17 March, 1994, *Bone Marrow Transplantation*, Abstract No. 485.
 28. Nemet D, Maravić N, Tomašković M, Labar B, Bogdanić V, Mrić M, Dobrić I, Skerlev M, Šneller V. Induction of graft-versus-host disease by administration of Cyclosporin A after ABMT for haematological malignancies, Congress Abstract No 161, First Meeting of the European Haematology Association, Brussels, Belgium, 2-5 June, 1994. *Brit J Haematol* 1994; 87 (Suppl 1):41.
 29. Labar B, Bogdanić V, Mrić M, Nemet D, Radman I, Zupančić-Šalek S, Kovačević-Metelko J, Aurer I, Maravić N, Šneller V. Allogeneic bone marrow transplantation for acute leukaemia - a ten year of Zagreb experience, Abstract No 149, First Meeting of the European Haematology Association, Brussels, Belgium, 2-5 June, 1994. *Brit J Haematol* 1994; 87 (Suppl 1):38.
 30. Skodlar J, Nemet D, Labar B, Petrovečki M, Sučić M, Golubić-Ćepulić B, Bogdanić V, Mrić M, Marušić M. Influence of peripheral blood cells on haematopoietic recovery after autologous bone marrow transplantation, Abstract No. 178, First

- Meeting of the European Haematology Association, Brussels, Belgium, 2-5 June, 1994. *Brit J Haematol* 1994; 87 (Suppl 1):45.
31. Aurer I, Labar B, Nemet D, Ajduković R, Bogdanić V, Gale RP. High incidence of conservative RAS mutations in acute myeloid leukemia. Abstract No. 461. First Meeting of the European Haematology Association, Brussels, Belgium, 2-5 June, 1994. *Brit J Haematol* 1994; 87 (Suppl 1):118.
 32. Mrsić M, Labar B, Radman I, Kovačević-Metelko J, Sertić D, Nemet D, Bogdanić V, Hitrec V, Boban D, Marković M, Sučić M, Davidović-Mrsić S, Klarin I. Treatment outcome for patients with myelodysplastic syndrome. Abstract No. 673, First Meeting of the European Haematology Association, Brussels, Belgium, 2-5 June, 1994. *Brit J Haematol* 1994; 87 (Suppl 1):172.
 33. Stryckmans P, Muus P, Marie JP, Fillet G, Labar B, Peetermans M, Kurstjens J, Efira A, Paulus R, Roozendaal K, Schaafsma R, Jakšić B, Feremans W, Verhest A, Bernier M, Dardenne M, Solbu G, de Witte T, Zittoun R, Suciu S. Adult Ph+ acute lymphoblastic leukemia in ALL-3 EORTC Study. 1995, *Blood* 84(Suppl. 1):145a.
 34. Nemet D, Labar B, Bogdanić V, Mrić M, Skodlar J, Patrovečki M, Radman I, Kovačević-Metelko J, Kalenić S, Sertić D, Serventi-Seiwerth R, Boban D. ABMT versus chemotherapy as consolidation for acute leukaemia in first remission - A prospective single centre study. *Bone Marrow Transplantation*, 1995; 15 (Suppl 2): S55, Abstract No 240, Abstracts of the 21st Annual Meeting of the EBMT, March 19-23, 1995, Davos Switzerland.
 35. Kelemen E, Labar B, Bogdanić V, Mistrik M, Masszi T, Nemet D, Mrić M, Denes R, Lutz D, on behalf of the International Society for Chemo-Immunotherapy (IGCI), Austria. Allogeneic bone marrow transplantation for chronic myelogenous leukaemia -IGCI experience, *Bone Marrow Transplantation*, 1995; 15 (Suppl 2): S18, Abstract No 97, Abstracts of the 21st Annual Meeting of the EBMT, March 19-23, 1995, Davos Switzerland.
 36. Labar B, Masszi T, Morabito F, Mistrik M, Bogdanić V, Nemet D, Mrić M, Lutz D, on behalf of the International Society for Chemo-Immunotherapy (IGCI), Austria. Allogeneic bone marrow transplantation for acute leukaemia - IGCI experience, *Bone Marrow Transplantation*, 1995; 15 (Suppl 2): S63, Abstract No 247, Abstracts of the 21st Annual Meeting of the EBMT, March 19-23, 1995, Davos Switzerland.
 37. Jandrlić M, Kalenić S, Labar B, Jakić-Razumović J, Nemet D, Bogdanić V, Mrić M. Fungal infections in haematological malignancies after intensive chemotherapy and marrow transplantation. *Bone Marrow Transplantation*, 1995; 15 (Suppl 2): S118, Abstract No 492, Abstracts of the 21st Annual Meeting of the EBMT, March 19-23, 1995, Davos Switzerland.
 38. Skerlev M, Labar B, Bogdanić V, Pavelić K, Sertić D, Nemet D, Mrić M, Dobrić I. A giant condilomata fo Buscke - Lowenstein after allogeneic bone marrow transplantation. *Bone Marrow Transplantation*, 1995; 15 (Suppl 2): S126, Abstract No 525, Abstracts of the 21st Annual Meeting of the EBMT, March 19-23, 1995, Davos Switzerland.
 39. Bogdanić V, Jakić -Razumović J, Labar B, Užarević B, Unušić J, Nemet D, Aurer I, Mrić M. Immuniphenotyping of cell infiltrates in chronic skin graft versus host

- reaction (cGVHR). *Bone Marrow Transplantation*, 1995; 15 (Suppl 2): S146, Abstract No 604, Abstracts of the 21st Annual Meeting of the EBMT, March 19-23, 1995, Davos Switzerland.
40. Mrsić M, Labar B, Bogdanić V, Nemet D, Klarin I. Serum Cyclosporin concentration after allogeneic bone marrow transplantation. *Bone Marrow Transplantation*, 1995; 15 (Suppl 2): S147, Abstract No 608, Abstracts of the 21st Annual Meeting of the EBMT, March 19-23, 1995, Davos Switzerland.
 41. Nemet D, Batinić D, Užarević B, Skodlar J, Petrovečki M, Bogdanić V, Mrić M, Sučić M, Golubić B, Bojanić I, Kalenić S, Labar B. Transplantation of autologous blood CD34+ progenitor cells positively selected using the Ceprate immunoaffinity separation system. Abstract. 22nd Annual Meeting of the European Blood and Marrow Transplant Group (EBMT), March 3-7, 1996, Vienna, Austria. *Bone Marrow Transplantation* 1996; 17 (Suppl 1): S139.
 42. Bogdanić V, Labar B, Maravić N, Skodlar J, Nemet D, Mrić M, Aurer I, Batinić D, Kaštelan A. Transplantation of allogeneic peripheral blood stem cells mobilised by recombinant human granulocyte colony-stimulating factor. Abstract. 22nd Annual Meeting of the European Blood and Marrow Transplant Group (EBMT), March 3-7, 1996, Vienna, Austria. *Bone Marrow Transplantation* 1996; 17 (Suppl 1): S114.
 43. Mrić M, Nemet D, Bogdanić V, Skodlar J, Čepulić B, Batinić D, Petrovečki M, Radman I, Mrić S, Maravić N. Blood stem cell transplantation in the treatment of haematological malignancies. Abstract. 22nd Annual Meeting of the European Blood and Marrow Transplant Group (EBMT), March 3-7, 1996, Vienna, Austria. *Bone Marrow Transplantation* 1996; 17 (Suppl 1): S137.
 44. Nemet D, Batinić D, Užarević B, Skodlar J, Petrovečki M, Bogdanić V, Mrić M, Maravić N, Sučić M, Golubić B, Bojanić I, Kalenić S, Labar B. Transplantation of positively selected autologous blood CD34+ progenitor cells or unmanipulated PBSC -Comparison of haematologic recovery, Second Meeting of the European Haematology Association, Paris, France, 29 May-1 June 1996. Abstract, *Brit J Haematol* 1996; 93 (Suppl 2):246.
 45. Aurer I, Labar B, Nemet D, Ajduković R, Bogdanić V, Gale RP. FMS mutations in acute myeloid leukemia and myelodysplastic syndrome detected with DNA sequencing and allele-specific restriction analysis (ASRA). Second Meeting of the European Haematology Association, Paris, France, 29 May-1 June 1996. Abstract, *Brit J Haematol* 1996; 93 (Suppl 2):36.
 46. Mrić M, Labar B, Nemet D, Batinić D, Bogdanić V, Užarević B, Boban D, Marković-Glamočak M, Sučić M, Hitrec V, Radman I, Šalek-Zupančić S, Mrić S, Maravić N. Unusual surface immunophenotype in acute leukaemia confers a poor prognosis. Second Meeting of the European Haematology Association, Paris, France, 29 May-1 June 1996. Abstract, *Brit J Haematol* 1996; 93 (Suppl 2):59.
 47. Muus P, Zittoun R, Hayat M, Mandelli F, Willemze R, de Witte T, Stryckmans P, Labar B, Bernemen Z, Archimbaud E, Petti MC, Jehn U, Solbu G, Dardenne M, Suci S. Long-term survivors after AML; follow up on survival and late effects of the AML 5, 6 and 8 studies of the EORTC Leukemia Cooperative Group and GIMEMA. *Blood*, 88(Suppl. 1), 1996; p.81a.
 48. De Witte T, Suci S, Boogaerts M, Labar B, Archimbaud E, Aul C, Selleslag D, Ferrant A, Weijermans P, Mandelli F, Amadori S, Jehn U, Muus P, DeMuyneck H,

- Dardenne M, Willemze R, Gratwohl A, Apperley J. The influence of cytogenetic abnormalities on treatment outcome after intensive antileukemic therapy for patients with high risk MDS and AML following MDS. A joint study of the EORTC, EBMT, SAKK and GIMEMA leukemia groups. *Blood*, 88(Suppl. 1), 1996; p. 454a.
49. Mattijsen V, De Witte T, Suciú S, Boogaerts M, Labar B, Archimbaud E, Aul C, Selleslag D, Ferrant A, Weijermans P, Mandelli F, Amadori S, Jehn U, Muus P, DeMuynck H, Dardenne M, Willemze R, Gratwohl A, Apperley J. The prognostic impact of the presence of an HLA-identical donor on patients with high risk MDS and AML following MDS treated with an intensive antileukemic regimen. A joint study of the EORTC, EBMT, SAKK and GIMEMA leukemia Groups. *Blood*, 88(Suppl. 1), 1996; p. 480a.
 50. Keating S, Suciú S, Mandelli F, de Witte T, Zittoun R, Archimbaud E, Labar B, Resegotti L, Meloni G, Rotoli B, Broccia G, Fazi P, Dardenne M, Willemze R. Feasibility of autologous BMT or PBSCT for patients with AML in first CR: A preliminary analysis of the AML 10 study of the leukemia cooperative group of the EORTC and GIMEMA. *Bone Marrow Transplant* 19(suppl. 1), 1997; p. S79.
 51. Skodlar J, Batinić D, Nemet D, Golubić-Čepulić B, Bojanić I, Mrić M, Maravić N, Labar B. Periphera blood progenitor cell harvesting in patients with hematological malignancies and solid tumors. *Bone Marrow Transplant* 19(suppl. 1), 1997; p. S47.
 52. Nemet D, Batinić D, Užarević B, Skodlar J, Petrovečki M, Bogdanić V, Mrić M, Maravić N, Sučić M, Golubić B, Bojanić I, Kalenić S, Labar B. POsitive selected haematopoietic CD34+ progenitors provide identical haematopoietic engraftment as unmanipulated PBSC. *Bone Marrow Transplant* 19(suppl. 1), 1997; p. S54.
 53. Labar B, Nemet D, Bogdanić V, Mrić M, Radman I, Boban D, Batinić D, Petrovečki M, Skodlar J, Golubić B, Kalenić S, Vrtar M, Markulin-Grgić Lj, Metelko-Kovačević J, Šalek-Zupančić S, Aurer I, Maravić N, Kaštelan A. Allogeneic versus autologous bone marrow transplantation versus chemotherapy for patients with acute myelogenous leukaemia in first complete remission. *Bone Marrow Transplant* 19(suppl. 1), 1997; p. S99.
 54. Bogdanić V, Aurer I, Nemet D, Kaštelan A, Mrić M, Maravić N, Hitrec V, Boban D, Labar B. Treatment of chronic myeloid leukemia (CML) in relapse after umbilical cord blood transplantation (UCBT). *Bone Marrow Transplant* 19(suppl. 1), 1997; p. S176.
 55. Gerhartz HH, Zwierzina H, Suciú S, Walther J, Dardenne M, Neuwirtova R, Fenaux P, Beksac M, Harousseau JL, Louwagie A, Thyss A, Fiere D, Coiffier B, Baumelou F, Labar B, Solbu G, Willemze R. Randomized – 3 arm phase III study of interleukin 3 (IL-3), or granulocyte/macrophage colony-stimulating factor (GM-CSF) as an adjuvant to low doses of cytosine arabinoside (LD-AraC) for the treatment of high-risk myelodysplastic syndromes (HR-MDS), 39th Annual Meeting of American Society of Hematology, San Diego CA 1997, *Blood*, 90 (Suppl. 1), 1997;p.85a.
 56. Keating S, Suciú S, Mandelli F, De Witte T, Willemze R, Archimbaud E, Hayat M, Rotoli B, Labar B, Resegotti L, Fazi P, Dardenne M, Zittoun R. Autologous BMT or PSCT for patients with AML in first CR: A preliminary analysis of the AML 10 study of the leukemia cooperative group (LCG) of the EORTC and GIMEMA. 39th

- Annual Meeting of American Society of Hematology, San Diego CA 1997, Blood, 90 (Suppl. 1), 1997:p. 235a.
57. De Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C, Selleslag D, Ferrant A, Wijermans P, Mandelli F, Amadori S, Jehn U, Muus P, DeMuynck H, Dardenne M, Zittoun R, Willemze R, Gratwohl A, Apperley J. Autologous stem cell transplantation for patients with poor risk MDS and secondary AML (sAML). A joint study of the EORTC, ABMT, SAKK and GIMEMA leukemia groups. 39th Annual Meeting of American Society of Hematology, San Diego CA 1997, Blood, 90 (Suppl. 1), 1997:p.583a.
 58. Ivanković Z, Gojčeta K, Golubić B, Plenković F, Labar B. Thrombomatch^R and Platelet-associated IgG (PAIgG): Standard deviation helps in Diagnosis of Immune Thrombocytopenia (IT). 25th Congress of the International Society of Blood Transfusion, Vox Sang 74(Suppl 1):1396, 1998.
 59. Mrišić M, Labar B, Bogdanić V, Nemet D, Radman I, Metelko-Kovačević J, Aurer I, Zupančić-Šalek S, Sertić D, Pisk M. Allogeneic BMT for acute lymphoblastic leukemia in adults – long term survival. 24th Annual Meeting European Group for Blood and Marrow Transplantation, Courmayeur, Italy, Bone Marrow Transplant 21(Suppl 1.):S6, 1998.
 60. De Witte T, van Biezen A, Hermans J, Suciu S, Dardenne M, Labar B, Archimbaud E, Aul C, Selleslag D, Ferrant A, Meloni G, Brunet Mauri S, Carella A, Laporte J, DeMuynck H, Niederwieser D, Gratwohl A, Apperley J. Autologous Stem Cell Transplantation (ASCT) for Patients with Myelodyslastic Syndrome and Secubdry Acute Myeloid Leukemia. 24th Annual Meeting European Group for Blood and Marrow Transplantation, Courmayeur, Italy, Bone Marrow Transplant 21(Suppl 1.):S10, 1998.
 61. Bojanić I, Golubić-Čepulić B, Nemet D, Batinić D, Užarević B, Petrovečki M, Skodlar J, Mrišić M, Radman I, Labar B. Collection of PBSC in Patients with Lymphoid Malignancies. 24th Annual Meeting European Group for Blood and Marrow Transplantation, Courmayeur, Italy, Bone Marrow Transplant 21(Suppl 1.):S175, 1998.
 62. Labar B, Nemet D, Mrišić M, Radman I, Skodlar J, Batinić D, Bogdanić V, Metelko-Kovačević J, Aurer I, Petrovečki M, Golubić-Čepulić B, Bojanić I, Pisk M. 24th Annual Meeting European Group for Blood and Marrow Transplantation, Courmayeur, Italy, Bone Marrow Transplant 21(Suppl 1.):S175, 1998.
 63. De Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C, Selleslag D, Ferrant A, Wijermans P, Mandelli F, Amadori S, Jehn U, Muus P, DeMuynck H, Dardenne M, Zittoun R, Willemze R, Gratwohl A, Apperley J. Intensive chemotherapy followed by stem cell transplantation for patients with poor-risk MDS and secondary AML (SAML), Blood 92 (Suppl 1):714a, 1998.
 64. Mrišić M, Labar B, Nemet D, Bogdanić V, Radman I, Golubić-Čepulić B, Batinić D, Skodlar J, Metelko-Kovačević J, Aurer I, Zupančić-Šalek S, Sertić D, Užarević B, Malenica B, Zadro R, Petrovečki M, Lukić M, Ivanković D, Markulin-Grgić Lj, Šantek F, Vrtar M, Mrišić S, Hitrec V, Boban D, Marković-Glamočak M, Sučić M, Kaštelan A, Kalenić S, Pisk M. Treatment of Acute Lymphoblastic leukaemia with chemotherapy alone or haematopoietic stem cell transplantation - long term follow up. Bone Marrow Transpl 25 (Suppl 1): S5, 2000.

65. Oosterveld M, Estey E, Muus P, Suciú S, Pierce S, Verhoef G, Labar B, Wijermans P, Aul C, Balhabri A, Mandelli F, Gratwohl A, Selleslag D, Dardenne M, Willemze R, de Witte T. Chemotherapy -only versus chemotherapy followed by transplantation in high risk MDS and S-AML: Two parallel studies adjusted for various prognostic factors. *Bone Marrow Transpl* 25 (Suppl 1):S59.m 2000
66. Golubić-Čepulić B, Bojanić I, Plenković F, Ivanković Z, Lukić M, Vukičević I, Šimunić N, Nemet D, Labar B. Adverse events in collection of peripheral blood hematopoietic progenitor cells during five year period. *Bone Marrow Transpl* 25 (Suppl 1): s271. 2000
67. Sandra Basic-Kinda, Igor Aurer, Dino Dujmovic, Ivo Radman, Dubravka Sertic, Klara Dubravcic, Koraljka Gjadrov-Kuvezdic, Drago Batinic, Mirna Susic, and Boris Labar. Continuous High-Dose Chlorambucil in Previously Untreated Patients with Chronic Lymphocytic Leukemia –Single-Center Experience. *Blood*. 2009; 114: 2372.
68. Michele Baccarani, Bengt Simonsson, Doris Lindörfer, Gianantonio Rosti, Antonio M Almeida, Andrija Bogdanovic, Richard E. Clark, Adriana Colita, Paul A. Costeas, Laimonas Griskevicius, Joelle Guilhot, Andrzej Hellmann, Karel Indrak, Edward Laane, Boris Labar, Tamas Masszi, Sandra Lejniece, Jiri Mayer, Gert Ossenkoppele, Panayiotis Panayiotidis, Kimmo Porkka, Susanne Saussele, Andreas Hochhaus, Juan Luis Steegmann, Josef Thaler, Anna Turkina, Gregor Verhoef, Andrey Zaritskey, Irena Preloznik Zupan, Francesca Rancati, Lara Montrucchio, Rüdiger Hehlmann, and Joerg Hasford. The European Treatment and Outcome Study (EUTOS) for Chronic Myeloid Leukemia (CML). A Prospective, Population-Based European Registry. *Blood*. 2009; 114: 4272.
69. M. G Aslanyan, S. M.C. Langemeijer, D. Cilloni, G. Saglio, JP Marie, R. Tang, B. Labar, R. Zadro, D. Batinic, S. Amadori, F. Lo Coco, T. Scheele, L. Kroeze, M. Massop, P. van Hoogen, E. Stevens, P. Muus, S. Suciú, L. Baila, E. W.A. Marijt, R. Willemze, T. de Witte, B. van der Reijden, and J. H. Jansen. Incidence and Clinical Impact of *TET2* Mutations in Acute Myeloid Leukemia Patients Treated within the EORTC/GIMEMA AML-12/06991 AML Trial. *Blood*. 2009; 114: 2609.
70. Heinz Ludwig, Zdenek Adam, Elena Tóthová, Roman Hajek, Boris Labar, Miklós Egyed, Ivan Spicka, Johannes Drach, Heinz Gisslinger, Ingrid Kuhn, Niklas Zojer, Zoran Birovljev, and Axel Hinke. Thalidomide-Interferon Vs. Interferon Maintenance Therapy After Thal-Dex Vs. MP Induction Therapy in Elderly Patients with Multiple Myeloma. *Blood*. 2009; 114: 2891.
71. Roelof Willemze, Stefan Suciú, Franco Mandelli, Stijn J.M. Halkes, Jean-Pierre Marie, Boris Labar, Adriano Venditti, Petra Muus, Martin Mistrik, Bruno Rotoli, Domenico Magro, Lorella Melillo, Dominique Bron, Francesco Fabbiano, Dominik L.D. Selleslag, Domenico Pastore, Silvia maria Trisolini, Paola Fazi, Christelle Vandermaelen, Liliana Baila, Marco Vignetti, Sergio Amadori, T. M. de Witte, and Giovanna Meloni. Value of Low Dose IL-2 as Maintenance Following Consolidation Treatment or Autologous Transplantation in Acute Myelogenous Leukemia (AML) Patients Aged 15-60 Years Who Reached CR After High Dose (HD-AraC) Vs Standard Dose (SD-AraC) Cytosine Arabinoside

- During Induction: Results of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups. *Blood*. 2009; 114: 791.
72. Sucic M, Hodak N, Markovic-Glamocak M, Ries S, Gjadrov-Kuvedzic K, Labar B. P27KIP1 in acute myeloid leukemia. *Haematologica* 2010; (suppl.2):506, abs. 1235.
 73. Dujmovic D, Aurer I, radman I, Serventi-Seiwerth R, Stern-Padovan R, Dotlic S, Dubravcic K, Santek F, Labar B. Addition of rituximab to high-dose methotrexate-based chemotherapy improves outcomes in adult Burkitt lymphoma patients. *Haematologica* 2010; (suppl.2):625, abs. 1582.
 74. Michael Lubbert, Stefan Suci, Uwe Platzbecker, Aristoteles A.N. Giagounidis, Dominik Selleslag, Boris Labar, Ulrich Germing, Andrea Kuendgen, Helmut R. Salih, Petra Muus, Björn Rüter, Arnold Ganser, Carlo Aul, Theo de Witte, and Pierre W. Wijermans Prognostic Importance of Duration of MDS Prior to Randomization Between Decitabine (DAC) Vs. Best Supportive Care (BSC) In Elderly IPSS Intermediate-2 and High Risk MDS Patients: Results of the 06011 EORTC-GMDSSG Phase III Trial. *Blood*, Nov 2010; 116: 4024.
 75. Roelof Willemze, Stefan Suci, Franco Mandelli, Stijn J.M. Halkes, Jean-Pierre Marie, Boris Labar, Adriano Venditti, Petra Muus, Martin Mistrik, Andrea Camera, Domenico Magro, Lorella Melillo, Dominique Bron, Silvana Magrin, Dominik Selleslag, Domenico Pastore, Silvia Trisolini, Paola Fazi, Matthias Karrasch, Marco Vignetti, Sergio Amadori, Theo M. de Witte, and Giovanna Meloni. High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) During Induction and IL-2 Vs Observation After consolidation/Autologous Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML): Final Report of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups on the Value of Low Dose IL-2 Maintenance. *Blood*. 2011; 118: 3612.
 76. Roelof Willemze, Stefan Suci, Franco Mandelli, Giovanna Meloni, Boris Labar, Stijn J.M. Halkes, Petra Muus, Martin Mistrik, Giordina Specchia, Francesco Fabbiano, Francesco Nobile, Marco Sborgia, Andrea Camera, Dominik Selleslag, Francois Lefrere, Domenico Magro, Giuseppe Leone, Nicola Cantore, Meral Beksac, Zwi Berneman, Xavier Thomas, Lorella Melillo, Dominique Bron, Georges Fillet, Jose E. Guimaraes, Sergio Amadori, Paola Fazi, Matthias Karrasch, Marco Vignetti, Theo de Witte, and Jean-Pierre Marie. High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) During Induction and IL-2 Vs Observation After Consolidation/Autologous Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML): Final Report of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups on the Value of High Dose AraC. *Blood*, 2011; 118: 257.

b) **na domaćim skupovima**

1. Čepelja Z., Labar B., Bogdanić V., Grgić Z., Stojanovski-Bubanj A.: Vrijednosti LDH kod bolesnika s malignim limfomima. Zbornik radova, Hematološki dani, Split, 1980, str. 493-499.
2. Labar B.: Liječenje akutnih leukemija u odraslih, Zbornik radova 7. Kongresa liječnika Hrvatske, Zagreb, 1982., str 139.

3. Labar B, Kovačević J.: Adenozin trifosfat i difosfoglicerat u eritrocitima bolesnika s mijeloproliferativnim sindromom, Zbornik radova, IV Kongres Hematologa i Transfuziologa Jugoslavije, Beograd, Bilten hematol transf., 10:176, 1982.
4. Labar B, Bogdanić V.: Prognostički faktori u aplastične anemije, Zbornik radova IV Kongresa Hematologa i Transfuziologa Jugoslavije, Beograd, Bilten hematol. transf., 10:253, 1982.
5. Labar B, Bogdanić V, Kaštelan A, Grgičević D, Vrtar M, Grgić-Markulin Lj, Francetić I, Boban D, Balabanić-Kamauf B, Dobrić I.: Bone marrow transplantation in Zagreb, Yugoslavia, IInd International Symposium on fetal liver transplantation, Pesaro, Italy, 1984, p. 65.
6. Bogdanić V, Čvorišćec D, Stavljenić A, Labar B.: Determination of urinary enzymes in patients treated with bone marrow transplantation, 11th Annual Meeting of the EBMT, Bad Hofgastein, Austria, 1985, p.54.
7. Labar B, Bogdanić V, Čepelja Z, Kovačević J, Francetić I, Balabanić-Kamauf B, Grgičević D, Kaštelan A.: Aplastic anemia: treatment with bone marrow transplantation or antilymphocyte globulin, 11th Annual Meeting of the EBMT, Bad Hofgastein, Austria, 1985., p. 54.
8. Batinić D, Boranić M, Tiefenbach A, Jakšić B, Labar B, Konja J, Rajić Lj, Kardum I, Šušterčić D, Nakić M, Bogdanić V, Nemet D, Boban D.: Primjena monoklonskih antitijela u klasifikaciji i dijagnostici akutnih leukemija, V Kongres Hematologa i Transfuziologa Jugoslavije s međunarodnim učešćem, Maribor, 1986, Sažetak, Bilten Hematol. Transf., 1986:14(1):16.
9. Bogdanić V, Čepelja Z, Kovačević J, Nemet D, Labar B.: Liječenje akutnih leukemija i mijelodisplazija malim dozama citozin arabinozida, V Kongres Hematologa i Transfuziologa s međunarodnim učešćem, Maribor, Sažetak, Bilten Hematol. Transf., 1986; 14(1):50.
10. Labar B, Bogdanić V, Nemet D, Kaštelan A, Vrtar M, Grgić-Markulin Lj, Boban D, Francetić I, Balabanić-Kamauf B.: Transplantacija koštane srži u liječenju leukemija, V Kongres Hematologa i Transfuziologa Jugoslavije s međunarodnim učešćem, Maribor, Sažetak, Bilten Hematol. Transf., 1986; 14(1):53.
11. Nemet D, Bogdanić V, Labar B, Brkljačić V, Skodlar J.: Transfuziološko liječenje bolesnika s leukemijom u toku transplantacije koštane srži, V Kongres Hematologa i Transfuziologa Jugoslavije s međunarodnim učešćem, Maribor, Sažetak, Bilten Hematol. Transf., 1986; 14(1):54.
12. Čvorišćec D., Stavljenić A., Labar B.: Enzimurija i Tamm-Horsfall proteinurija u bolesnika nakon transplantacije koštane srži, 7 Kongres medicinskih biokemičara Jugoslavije, Novi Sad, J M B, 6:20, 1987.
13. Labar B.: Imunološki i biokemijski aspekti alogenične transplantacije koštane srži, 7 Kongres medicinskih biokemičara Jugoslavije, Novi Sad, J M B, 6:57, 1987.
14. Labar B, Bogdanić V, Nemet D.: Experience with allogeneic bone marrow transplantation for severe aplastic anemia and leukemia. Four years experience with 55 patients in Zagreb (Yugoslavia), International Symposium on bone marrow transplantation, Leipzig, 1987., p. 41.
15. Labar B.: Bone marrow transplantation for acute leukemia in Zagreb, Abstract, Seminar "New Trends in the Treatment of Acute Leukemia", Dubrovnik, 1987., p L-21.

16. Nemet D, Labar B, Bogdanić V, Kovačević J, Mrić M, Čepelja Z.: Invasive aspergillosis during intensive leukaemia treatment -cases report, Abstract, Seminar "New Trends in the Treatment of Acute Leukemia" Dubrovnik, 1987., p. P-9.
17. Dobrić I, Labar B, Bogdanić V, Kinsky A, Vujasinović S, Škrinjar Lj.: Sclerodermiform changes of graft-versus-host disease, Abstract, Seminar "New Trends in the Treatment of Acute Leukemia", Dubrovnik, 1987., p. P-13.
18. Bogdanić V, Čvorišćec D, Labar B, Nemet D, Mrić M, Pavletić Ž.: Immunoglobulins after allogeneic bone marrow transplantation, Abstract, Seminar "New Trends in the Treatment of Acute Leukaemia", Dubrovnik, 1987, p. P-19.
19. Nemet D, Bogdanić V, Labar B, Pavletić Z, Mrić M, Juričić M, Čvorišćec D.: IgE values in patients with bone marrow transplant, Abstract, Seminar "New trends in the treatment of Acute Leukaemia", Dubrovnik, 1987, p. P-19.
20. Nemet D, Labar B, Bogdanić V, Vrtar M, Presečki V, Balabanić-Kamauf B, Kaštelan A, Grgić-Markulin Lj, Mrić M, Pavletić Ž.: Low incidence of interstitial pneumonitis after bone marrow transplantation: assessment of risk factors, Abstract, Seminar "New trends in the treatment of Acute Leukaemia", Dubrovnik, 1987, p. P-17.
21. Labar B, Bogdanić V, Nemet D, for the BMT team: Experience with bone marrow transplantation for leukemia and aplastic anemia, International Symposium "New Developments in treatment of leukemias: Aclarubicin", Istanbul, 1988.
22. Labar B, Jakšić B, Malešević D, Nemet D, Minigo H, Bogdanić V, Mrić M, Planinc-Perajica A.: Aclacinomycin plus Cytosine-Arabinoside for treatment of de-novo Acute Myelocytic Leukemia, International Symposium, "New Developments in treatment of leukemias: Aclarubicin", Istanbul, 1988.
23. Kovačević J, Bogdanić V, Labar B, Nemet D, Čepelja Z, Mrić M. Liječenje akutnih mijeloidnih leukemija i mijelodislazija malim dozama citozin-arabinozida. Sažetak. Bilten za hematologiju i transfuziologiju 1988;16(1). IX Jugoslavenski hematološko-transfuziološki dani, Novi Sad, 1988.
24. Zupančić S, Ficović P, Čepelja Z, Nemet D, Bogdanić V, Kovačević J, Labar B. Koagulacijske promjene u bolesnika s akutnom leukemijom. Ibid. str 1.38.
25. Boban D, Marković-Glamočak M, Batinić D, Nemet D, Labar B. Korelacija citomorfološke klasifikacije i imunofenotipizacije akutnih leukemija. Ibis. str 1.42.
26. Batinić D, Labar B, Bogdanić V, Nemet D, Žalud I, Marušić M. Imunološka fenotipizacija ljudskih leukemija na protočnom razvrstaču stanica. Ibid. str 1.45.
27. Žalud I, Pavletić Ž, Nemet D, Labar B, Batinić D, Marušić M. Fenotipizacija limfatičkih stanica normalne ljudske koštane srži na protočnom razvrstaču stanica. Ibid., str 1.46.
28. Bogdanić V, Labar B, Nemet D, Mrić M, Kaštelan A, Vrtar M, Grgić Markulin Lj. Transplantacija alogenične koštane srži u liječenju akutnih leukemija. Sažetak. Bilten za hematologiju i transfuziologiju, Ibid. str. 4.2.
29. Nemet D, Labar B, Bogdanić V, Kaštelan A, Mrić M, Pavletić Ž, Vrtar M i sur. Transplantacija koštane srži u liječenju kronične mijeloidne leukemije. Ibid. str. 4.3.
30. Nemet D, Labar B, Bogdanić V, Kolevska T, Mrić M, Pavletić Ž i sur. Liječenje akutnih leukemija transplantacijom autologne koštane srži - prva iskustva Transplantacijskog tima KBC Rebro. Ibid. str. 4.4.
31. Marušić M, Labar B, Bogdanić V, Nemet D, Pavletić Ž, Rudolf M, Kolevska T. Imunološki oporavak nakon presaživanja alogenične koštane srži. Ibid. str 4.9.

32. Kolevska T, Nemet D, Labar B, Marušić M. Neki parametri in-vitro rasta normalne koštane srži. *Ibid.* str. 4.10.
33. Bogdanić V, Labar B, Nemet D, Kaštelan A, Mrsić M, Plavšić F, Dobrić I. Reakcija transplantata protiv primaoca (GVHD) nakon transplantacije alogenične koštane srži. Sažetak. *Ibid.* str. 4.12.
34. Dobrić I, Vujasinović S, Labar B, Bogdanić V, Nemet D. Reakcija transplantata protiv primaoca (GVHD); kliničke i mikromorfološke promjene kože. *Ibid.* str. 4.13.
35. Pavletić Ž, Labar B, Bogdanić V, Nemet D, Mrsić M, Stavljenić A, Čvorišćec D. Neopterin u dijagnostici komplikacija nakon alogenične transplantacije koštane srži. *Ibid.* str. 4.14.
36. Kalenić S, Balabanić-Kamauf B, Bogdanić V, Nemet D, Mrsić M, Labar B. Učestalost bakterijskih i gljivičnih infekcija u bolesnika liječenih transplantacijom koštane srži. *Ibid.* str. 4.15.
37. Radman I, Nemet D, Bogdanić V, Presečki V, Mrsić M, Pavletić Ž, Labar B. Niska učestalost intersticijskog pneumonitisa u bolesnika liječenih transplantacijom koštane srži-procjena rizika. *Ibid.* str. 4.16.
38. Mrsić M, Bogdanić V, Labar B, Nemet D, Pavletić Ž, Presečki V, Kovačević-Metelko J. Profilaksa infekcija herpes simplex virusom u bolesnika liječenih transplantacijom koštane srži. Sažetak. *Ibid.* str. 4.17.
39. Pavletić Ž, Bogdanić V, Nemet D, Mrsić M, Juričić D, Čvorišćec D, Labar B. IgE u bolesnika liječenih alogeničnom transplantacijom koštane srži. *Ibid.* str. 4.18.
40. Nemet D, Labar B, Jakšić B. Prognostic classification of chronic myeloid leukaemia. Abstract. str. 172. XII Congress of the International Society of Hematology, Milan, Italy, August 28-September 2, 1988.
41. Bogdanić V, Nemet D, Pavletić Ž, Mrsić M, Vrtar M, Grgić-Markulin Lj, Kaštelan A, Kalenić S, Kerhin-Brkljačić V, Boban D, Labar B. Allogeneic bone marrow transplantation for acute leukemia in Zagreb, Yugoslavia. Abstract, *Ibid.* str. 398.
42. Pavletić Ž, Nemet D, Bogdanić V, Mrsić M, Juričić M, Čvorišćec D, Labar B. Elevated IgE values in patients with bone marrow transplant and acute GVHD. Abstract, *Ibid.* str. 398.
43. Labar B, Bogdanić V, Nemet D, Kovačević J, Pavletić Ž, Mrsić M. Allogeneic bone marrow transplantation versus chemotherapy for AML-A prospective study from Zagreb, Yugoslavia. Abstract. *Ibid.* str. 285.
44. Nemet D, Labar B, Bogdanić V, Kovačević J, Mrsić M, Aurer I, Pavletić Ž. Treatment of acquired aplastic anaemia (AA) with antilymphocyte globuline (ALG) or bone marrow transplantation (BMT)-Zagreb experience. Abstract p. 153. XV Annual Meeting of the European Bone Marrow Transplant Group, February 26-March 2, 1989, Badgastein, Austria.
45. Mrsić M, Bogdanić V, Nemet D, Plavšić F, Pavletić Ž, Labar B. Cyclosporine plus methotrexate versus cyclosporine alone for graft-versus-host disease prophylaxis following bone marrow transplantation. *Ibid.* p. 89.
46. Batinić D, Pavletić Ž, Kolevska T, Bogdanić V, Žalud I, Nemet D, Marušić M, Labar B. Lymphocyte subsets in normal human bone marrow harvested for routine clinical transplantation. *Ibid.* p. 174.
47. Labar B, Bogdanić V, Nemet D, Pavletić Ž, Mrsić M. Risk factors for acute graft-versus host disease. *Ibid.* p. 190.

48. Užarević B, Batinić D, Marušić M, Metikoš M, Nemet D, Pavletić Ž, Radman I, Labar B. Flow cytometric cell cycle analysis of blast cells in patients with acute leukemia: a prognostic significance. Seminar New Trends in the Treatment of Acute Leukemia, Dubrovnik, 1989, Abstract book, p 96.
49. Pavletić Ž, Aurer I, Labar B, Bogdanić V, Nemet D. Prostaglandin E2 for prevention of oral mucositis in patients with leukemia undergoing bone marrow transplantation: A randomized double-blind clinical trial. Ibidem p. 116.
50. Batinić D, Pavletić Ž, Kolevska T, Bogdanić V, Užarević B, Nemet D, Labar B, Marušić M. Further studies of the cell composition of bone marrow transplants. Ibid.p.123.
51. Skodlar J, Golubić B, Labar B, Bogdanić V, Mrić M, Nemet D, Gašparović V. ABO incompatibility in allogeneic bone marrow transplantation. Ibid. p. 124.
52. Jakić-Razumović J, Bogdanić V, Nemet D, Ščukanec-Špoljar M, Labar B. Main autopsy findings in bone marrow transplant patients with acute leukaemia. Ibid p. 125.
53. Nemet D, Labar B, Bogdanić V, Kolevska T, Skodlar J, Mrić M, Pavletić Ž, Kalenić S, Vrtar M, Marušić M, Markulin-Grgić Lj, Boban D, Francetić I. Transplantacija krioprezervirane autologne koštane srži u liječenju akutnih leukemija. II Jugoslovenski simpozij: Transfuzija u onkologiji, Zagreb, 1989, Sažetak, str. 11.
54. Pavletić Ž, Labar B, Marušić M, Bogdanić V, Nemet D, Mrić M, Petrovečki M, Užarević M, Marković J, Matek Z. Imunološki oporavak nakon transplantacije koštane srži. Ibid. str. 12.
55. Skodlar J, Golubić B, Labar B, Bogdanić V, Nemet D, Mrić M, Gašparović V. ABO inkompatibilnost u alogeničnoj transplantaciji koštane srži. Ibid. str. 14.
56. Labar B, Nemet D, Mrić M, Bogdanić V, Presečki V. et al. Aciklovir u liječenju bolesnika s Herpes simplex i Varicella zoster virus infekcijom nakon transplantacije koštane srži. Simpozij: Virolex (Aciklovir) u kemoterapiji herpetičnih oboljenja, Moskva, 1990, Zbornik radova.
57. Badanjak A, Nemet D, Kalenić S, Bogdanić V, Davila N, Francetić I, Labar B. Norfloxacin u prevenciji gram-negativnih infekcija u granulocitopeničnih bolesnika, usporedba s gentamicinom. Sažetak, ibid. str. 103.
58. Jandrlić M, Kalenić S, Jakić-Razumović J, Nemet D, Bogdanić V, Labar B. Gljivične infekcije u bolesnika s malignom hemoblastozom: Usporedba mikoloških nalaza za života s obdukcijским nalazom. Sažetak, ibid. str. 105.
59. Boban D, Marković-Glamočak M, Sučić M, Batinić D, Nemet D, Labar B. Korelacija citomorfološke i imunološke klasifikacije akutnih leukemija. Sažetak. ibid str. 116.
60. Petrovečki D, Marušić M, Nemet D, Labar B. Analiza staničnog ciklusa blasta u bolesnika s akutnim leukemijama protočnom citometrijom, Sažetak, ibid str. 123.
61. Ajduković R, Kovačević J, Bogdanić V, Nemet D, Pavletić Ž, Radman I, Zupančić-Šalek S, Labar B. Liječenje mijelodisplastičnog sindroma s granulocitno-makrofagnim činiocem rasta. Sažetak, ibid. str. 300.
62. Bogdanić V, Labar B, Nemet D. Transplantacija alogenične koštane srži u liječenju akutne leukemije-Zagrebačko iskustvo. Sažetak, ibid. str. 399.
63. Nemet D, Labar B, Bogdanić V, Skodlar J, Petrovečki M, et al. Transplantacija krioprezervirane autologne koštane srži u liječenju akutnih leukemija i malignih limfoma. Sažetak, ibid. str. 400.

64. Mrsić M, Bogdanić V, Labar B, Nemet D, Vrtar M. Ozračenje cijelog tijela sa zaštitom pluća ili bez u pripremi za transplantaciju alogenične koštane srži. Sažetak. Ibid. str 401.
65. Nemet D, Labar B, Bogdanić V, Kovačević J, Radman I, Boban D. Primjena granulocitno-makrofagnog činioca rasta (rh GM-CSF) nakon transplantacije autologne koštane srži. Sažetak, Ibid str 405.
66. Kalenić S, Nemet D, Žele L, Tripković V, Bogdanić V, Labar B. Infekcije u bolesnika nakon transplantacije alogenične i autologne koštane srži (TKS)-sedmogodišnje iskustvo. Sažetak. ibid. str 407.
67. Sučić M, Marković-Glamočak M, Boban D, Bogdanić V, Nemet D, Labar B, Presečki V, [toos-Veić T. Citologija urina u bolesnika s transplantiranom koštanom srži i urinarnim infekcijama. Sažetak. Ibid. 409.
68. Bogdanić V, Labar B, Nemet D, Kovačević J, Radman I, Mrsić M. Bone marrow transplantation (BMT) versus immunosuppression in the treatment of aplastic anemia-Zagreb experience. Abstract, 17th Annual Meeting of the EBMTG, Cortina d'Ampezzo, Italy, 1991, p.82.
69. Nemet D, Labar B, Bogdanić V, Vrtar M, Mrsić M. Total body irradiation with or without lung shielding as conditioning for allogeneic bone marrow transplantation in early phase leukaemia. Abstract, ibid. p. 154.
70. Labar B, Pavletić Ž, Radman I, Bogdanić V, Nemet D, Aurer I, Sertić D. Prostaglandin E2 for prevention of oral mucositis in patients with leukaemia undergoing bone marrow transplantation. Abstract. Ibid. p. 176.
71. Jakic-Razumovic J, Labar B, Cor A, Radman I: Nucleolar organizer regions in malignant non-Hodgkin's Lymphomas. Abstract, Pathology Research and Practice 18716, 187:701, XIIIth European Congress of Pathology, Septembar 1-6, 1991, Ljubljana, Yugoslavia.
72. Mrsić M, Nemet D, Labar B, Bogdanić V, Radman I, Zupančić-Šalek S, Kovačević-Metelko J, Aurer I. Chemotherapy versus allogeneic bone marrow transplantation in adults with acute lymphoblastic leukaemia, Abstract No 19. The 18th Annual Meeting of the European Group for Bone Marrow Transplantation ,Stocholm, Sweden,May 31-June 3, 1992.
73. Labar B, Mrsić M, Nemet D, Bogdanić V, Radman I, Zupančić-Šalek S, Kovačević J, Aurer I. Comparison of chemotherapy versus allogeneic bone marrow transplantation in adults with acute myelogenous leukaemia. Ibidem, Abstract No 57.
74. Nemet D, Labar B, Bogdanić V, Kovačević J, Radman I, Mrsić M, Boban D. GM-CSF in patients with engraftment failure after autologous and allogeneic BMT, Ibidem, Abstract No 133.
75. Bogdanić V, Kaštelan A, Nemet D, Latin V, Patrovečki M, Konja J, Mrsić M, Aurer I, Labar B. Cord blood transplantation in a patient with chronic myelogenous leukaemia, Ibidem, Abstract No 254.
76. Mrsić M, Labar B, Bogdanić V, Nemet D, Dobrić I, Jakić- Razumović J. Copmbination of cyclosporine and methotrexate for GVHD prophylaxis : Long term follow-up. Ibidem, Abstract No 468.

77. Bogdanić V, Mrić M, Labar B, Nemet D, Dobrić I, Jakić- Razumović J, Serventi-Seiwerth R. High dose intravenous immunoglobulin ac GVHD prophylaxis. *Ibidem*, Abstract No 469.
78. Mrić M, Aurer I, Nemet D, Labar B, Bogdanić V, Radman I, Zupančić-Šalek S, Kovačević-Metelko J. Chemotherapy versus allogeneic bone marrow transplantation in adults with acute lymphoblastic leukaemia, XIVth International Congress of the Transplantation Society, Paris, August 16-21, 1992, Abstract No.500.
79. Bogdanić V, Kaštelan A, Nemet D, Latin V, Petrovečki M, Konja J, Mrić M, Aurer I, Labar B. Cord blood transplantation in patient with chronic myelogenous leukaemia, *Ibidem*, Abstract No.515.
80. Labar B, Nemet D, Bogdanić V, Mrić M, Radman I, Zupančić-Šalek S, Kovačević-Metelko J, Aurer I. Comparison of chemotherapy versus allogeneic bone marrow transplantation in adults with acute leukaemia, 24th Congress of the International Society of Haematology 23-27 August 1992, London, UK, Abstract No. 243.
81. Radman I, Kovačević- Metelko J, Labar B, Bogdanić V, Nemet D, Zupančić-Šalek S, Mrić M, Jakić- Razumović J. Is combined modality treatment superior to radiotherapy alone for CS IA-IIB Hodgkin's disease. *Ibidem*, Abstract No. 1234.
82. Radman I, Kovačević-Metelko J, Bogdanić V, Nemet D, Zupančić-Šalek S, Mrić M, Jakić- Razumović J, Labar B. Systemic chemotherapy of cutaneous lymphomas, *Ibidem*, Abstract No. 1235.
83. Mrić M, Labar B, Bogdanić V, Nemet D, Dobrić I, Jakić- Razumović J. Combination of cyclosporine and methotrexate for GVHD prophylaxis: Long term follow-up. *Ibidem*, Abstract No. 1308.
84. Mrić M, Labar B, Bogdanić V, Nemet D, Maravić N, Šneller V. Bone marrow transplantation for chronic myelogenous leukaemia - Zagreb experience. 19th Annual Meeting of the EBMTG, Garmish - Partenkirchen, Germany, January 17-21, 1993. Abstract No 108.
85. Bogdanić V, Labar B, Nemet D, Mrić M, Radman I, Maravić N, Šneller V. Bone marrow transplantation for aplastic anaemia using thoraco - abdominal irradiation and cyclophosphamide as a conditioning regimen - Zagreb experience. *Ibidem*. Abstract No 2907.
86. Nemet D, Petrovečki M, Labar B, Bogdanić V, Skodlar J, Batinić D, Radman I, Mrić M, Jukić T, Jinker AM, Marušić M, Boban D. The value of nucleated cell and progenitor cell (CFU-GM, BFU-E) monitoring in cryopreserved marrow for prediction of haematopoietic reconstitution following ABMT. *Ibidem*. Abstract No 4012.
87. Nemet D, Labar B, Bogdanić V, Skodlar J, Petrovečki M, Mrić M, Maravić N, Šneller V, Radman I, Kovačević-Metelko J, Kalenić S, Sertić D, Serventi-Seiwerth R, Boban D. Autologous bone marrow transplantation in the treatment of acute leukaemia - Zagreb experience, Abstract, Seminar "New Trends in the Treatment of Acute Leukaemias" Zagreb, June 7-10, 1993, Abstract book p. 28.
88. Mrić M, Labar B, Bogdanić V, Nemet D, Dobrić I, Jakić-Razumović J. Allogeneic BMT for acute leukaemia and GVHD prophylaxis, Abstract, *Ibidem*, p. 24.
89. Nemet D, Labar B, Bogdanić V, Mrić M, radman I, Kovačević-Metelko J, Sertić D, Serventi-Seiwerth R, Jukić T, Boban D. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) for haematopoietic recovery after ABMT. Abstract, *Ibidem*, p. 37.

90. Bogdanić V, Labar B, Nemet D, Mrić M, Radman I, Maravić N, Šneller V, Zupančić-Šalek S. Bone marrow transplantation for aplastic anaemia using thoraco-abdominal irradiation and cyclophosphamide as a conditioning regimen - Zagreb experience, Abstract, Ibidem, p. 41.
91. Bogdanić V, Kaštelan A, Nemet D, Latin V, Petrovečki M, Konja J, Mrić M, Aurer I, Labar B. Cord blood transplantation in patient with chronic myelogenous leukaemia, Abstract, Ibidem, p. 45.
92. Mrić M, Labar B, Nemet D, Bogdanić V, Maravić N, Šneller V. Ondasetron versus metoclopramide for prophylaxis of nausea and vomiting after marrow transplantation, Abstract, Ibidem, p. 46.
93. Labar B, Nemet D, Bogdanić V, Mrić M, Kalenić S, Francetić I, Presečki V, Maravić N, Šneller V. Management of infections in patients with acute leukaemia treated with intensive chemotherapy and bone marrow transplantation, Abstract, Ibidem, p. 50.
94. Aurer I, Labar B, Nemet D, Ajduković R, Bogdanić V, Gale R.P. RAS and FMS mutations in acute myeloid leukemia and myelodysplastic syndrome. Abstract, Ibidem, p. 57.
95. Hitrec V, Labar B, Nemet D, Jakšić B, Šušterčić D, Kardum I, Bogdanić V, Begović D, Mrić S. Cytogenetic abnormalities in acute leukaemia and myelodysplasia. Abstract, Ibidem, p. 59.
96. Maravić N, Solarić M, Bogdanić V, Nemet D, Minigo H, Ostojić S, Černelč P, Prebilić M, Mrić M, Radman I, Šneller V, Labar B. Pirarubicin vs daunorubicin in induction therapy for acute lymphoblastic leukaemia and lymphoblastic lymphoma - preliminary results. Abstract, Ibidem, p. 64.
97. Aurer I, Nemet D, Užarević B, Hitrec V, Mrić S, Zupančić-Šalek S, Radman I, Labar B. Mediastinal malignant teratoma and acute myeloid leukemia in a patient with Klinefelter's syndrome differ in DNA content. Abstract, Ibidem, p. 67.
98. Gašparović V, Maravić N, Nemet D, Labar B, Bogdanić V, Mrić M. Prevention of acute renal failure with verapamil in patients administered nephrotoxic drugs. Abstract, Ibidem, p. 72.
99. Sertić D, Labar B, Mrić M, Nemet D, Bogdanić V, Kovačević-Metelko J, Dobrić M. Immunosuppressive therapy for aplastic anaemia, Abstract, Ibidem, p. 76.
100. Maravić N, Nemet D, Labar B, Bogdanić V, Dobrić I, Skerlev M, Šneller V. Cyclosporine A induced graft-vs-host disease after autologous bone marrow transplantation. Abstract, Ibidem, p. 80.
101. Šneller V, Nemet D, Batinić D, Bogdanić V, Mrić M, Maravić N, Peter B, Labar B. Lymphocyte subpopulations in cord blood. Abstract, Ibidem, p. 81.
102. Bogdanić V, Labar B, Nemet D, Mrić M, Kovačević-Metelko J, Radman I, Zupančić-Šalek S, Aurer I, Maravić N, Šneller V. Bone marrow transplantation for chronic myelogenous leukaemia in 1st chronic phase - Zagreb experience. Abstract, Ibidem, p. 83.
103. Jandrlić M, Kalenić S, Jakić-Razumović J, Labar B, Bogdanić V, Nemet D. Infection in patients at risk - diagnostic value of the tests. Abstract, Ibidem, p. 85.
104. Mrić M, Labar B, Nemet D, Bogdanić V, Maravić N, Šneller V. Ondasetron versus Metoclopramide for prophylaxis of nausea and vomiting after intensive chemoradiotherapy. Abstract No 519. XIIth Meeting of the International Society of Haematology (European and African Division), Vienna, Austria, August 28-September 3, 1993.

105. Labar B, Bogdanić V, Nemet D, Mrsić M, Maravić N, Šneller V, Radman I, Kovačević-Metelko J, Zupančić-Šalek S, Aurer I, Sertić D, Serventi-Seiwerth R. Allogeneic BMT for acute leukaemia - Zagreb experience. Abstract No 529. Ibidem.
106. Labar B, Nemet D, Bogdanić V, Mrsić M, Kalenić S, Francetić I, Presečki V, Radman I, Kovačević J, Maravić N, Šneller V. Infections in patients with acute leukaemia treated with intensive chemotherapy and bone marrow transplantation. Congress Abstract: 3rd Croatian Congress of Clinical Microbiology, Zagreb, October 13-15, 1993. (in Croatian)
107. Labar B, Mrsić M, Skodlar J, Gašparović V, Maravić N, Bogdanić V, Nemet D. The influence of major ABO incompatibility in the outcome of allogenic BMT - Zagreb experience. Congress Abstract: I. International "Alps-Adriatic" Symposium of Transfusiologists and Immunohematologist of Slovenia, Austria, Bavaria, Croatia, Italy and Hungary, Maribor, October 15-16, 1993.
108. Petrovečki M, Nemet D, Skodlar J, Marušić M. Number of CFU-GM in autologous bone marrow transplant from patients with haematological malignancies. (In Croatian), First Croatian Congress of Clinical Citology, March 1995, Zagreb, Croatia
109. Nemet D, Labar B, Bogdanić V, Mrsić M, Skodlar J, Petrovečki M, Batinić D, Radman I, Kovačević-Metelko J, Boban D, Kalenić S, Sertić D, Serventi-Seiwerth R. Comparison of autologous BMT and chemotherapy in patients with acute myelogenous leukaemia in first remission, A prospective, single centre study. XIIIth Meeting of the International Society of Haematology (European and African Division), 1995, Istanbul, Turkiye, Abstract No 560.
110. Bogdanić V, Labar B, Aurer I, Nemet D, Mrsić M, Hitrec V, Zupančić-Šalek S, Boban D, Maravić N. Donor buffy coat infusion with or without chemotherapy for leukemia in relapse after marrow transplantation, Ibidem, Abstract No 562.
111. Maravić N, Labar B, Mrsić M, Nemet D, Bogdanić V, Radman I, Sertić D, Serventi R, Kovačević J, Šneller V. Randomised phase III study comparing Pirarubicin and Daunorubicin in the induction treatment for ALL and lymphoblastic lymphoma, Ibidem, Abstract No 521.
112. Mrsić M, Labar B, Nemet D, Bogdanić V, Radman I, Boban D, Batinić D, Kalenić S, Vrtar M, Grgić-Markulin Lj, Kaštelan A, Marušić M. Allogeneic bone marrow transplantation versus chemotherapy for patients with acute myelogenous leukaemia in first remission, Ibidem, Abstract No 566.
113. Radman I, Labar B, Nemet D, Sertić D, Kovačević-Metelko J, Zupančić-Šalek S, Mrsić M, Aurer I, Pulanić R, Jakić-Razumović J. Is primary gastric lymphoma of malt type curable with combination of ampicillin and omeprazole? - A case report. Ibidem, Abstract No 586.
114. Nemet D, Kovačević-Metelko J, Labar B, Mrsić M, Bogdanić V, Radman I, Skodlar J, Batinić D, Petrovečki M, Užarević B, Zupančić-Šalek S, Sertić D, Kalenić S, Grgić-Markulin Lj. Liječenje multiplog mijeloma transplantacijom autolognih matičnih hematopoetskih stanica. 1. Hrvatski kongres hematologa i transfuziologa, Zagreb, 7-9. studeni, 1995. Knjiga sažetaka, str. 22.
115. Kovačević J, Labar B, Radman I, Sertić D, Nemet D, Zupančić-Šalek S, Čvorišćec D, Boban D. Liječenje plazmocitoma VAD polikemoterapijskim programom. Ibidem, str 22.
116. Ajduković R, Svoboda-Beusan I, Nemet D, Mrsić M, Maravić N, Mažuran R, Dekaris D, Labar B. Određivanje višestruke otpornosti na lijekove u akutnih leukemija, Ibidem, str. 24.

117. Maravić N, Labar B, Mrišić M, Nemet D, Bogdanić V, Solarić M, Minigo H, Ostojić S, Černelc P, Prebilić M, Radman I, Kovačević J. Pirarubicin u liječenju ALL i limfoblastičnog limfoma, *Ibidem*, str. 24.
118. Batinić D, Užarević B, Boban D, Glamočak-Marković M, Sučić M, Hitrec V, Mrišić M, Nemet D, Bogdanić V, Marušić M, Labar B. neuobičajena akspresija biljega u akutnoj leukemiji odraslih - iskustvo Kliničkog bolničkog centra Zagreb, *Ibidem*, str. 27.
119. Skodlar J, Bojanić I, Golubić-epulić B, Batinić D, Petrovečki M, Užarević B, Mrišić M, Labar B, Nemet D. Sakupljanje matičnih stanica periferne krvi za transplantaciju u bolesnika s malignim bolestima, *Ibidem*, str. 28.
120. Batinić D, Užarević B, Nemet D, Skodlar J, Golubić B, Bojanić I, Petrovečki M, Mrišić M, Marušić M, Labar B. Učinkovitost izdvajanja CD34+ stanica periferne krvi metodom imunoadsorpcije na sistemu Ceprate-SC (CellPro), *Ibidem*, str. 29.
121. Bogdanić V, Labar B, Mrišić M, Nemet D, Radman I, Kalenić S, Vrtar M, Kerhin-Brkljačić V, Boban D, Merkulin-Grgić Lj, Maravić N. Transplantacija alogene koštane srži u liječenju akutne limfocitne leukemije u prvoj kompletnoj remisiji, *Ibidem*, str. 54.
122. Labar B, Mrišić M, Nemet D, Bogdanić V, Radman I, Kalenić S, Vrtar M, Kerhin - Brkljačić V, Boban D, Maravić N. Transplantacija alogene koštane srži u liječenju akutne mijeloične leukemije u prvoj kompletnoj remisiji, *Ibidem*, str. 54.
123. Nemet D, Labar B, Bogdanić V, Mrišić M, Skodlar J, Petrovečki M, Radman I, Batinić D, Kovačević-Metelko J, Kalenić S, Grgić-Markulin Lj, Vrtar M, Boban D, Sertić D, Serventi-Seiverth R. Transplantacija autologne koštane srži ili konsolidacijska kemoterapija u liječenju akutne limfoblastične leukemije u prvoj remisiji- Prospektivna studija KBC Rebro, *Ibidem*, str 54.
124. Nemet D, Labar B, Bogdanić V, Mrišić M, Skodlar J, Petrovečki M, Batinić D, Radman I, Kovačević-Metelko J, Boban D, Kalenić S, Grgić-Markulin Lj, Sertić D, Serventi-Seiwerth R. Transplantacija autologne koštane srži u usporedbi s kemoterapijom kao konsolidacijska terapija za akutnu mijeloičnu leukemiju u prvoj remisiji - Prospektivna studija KBC Rebro. *Ibidem*, str.54.
125. Nemet D, Labar B, Grahovac B, Mrišić M, Radman I, Bogdanić V, Hitrec V, Zaher D, Sertić D, Aurer I, Bošnjak A, Boban D. Trans-retinična kiselina u liječenju akutne promijelocitne leukemije i praćenje ostatne minimalne bolesti u remisiji detekcijom PML/RARa (retinoic-acid receptor a) transkripta reakcijom lančane polimeraze (PCR), *Ibidem*, str. 55.
126. Zaher D, Grahovac B, Nemet D, Mrišić M, Hitrec V, Labar B. Molekularna dijagnostika promijelocitne leukemije pomoću polimerazne lančane reakcije, *Ibidem*, str. 55.
127. Boban D, Sučić M, Marković-Glamočak M, Batinić D, Užarević B, Labar B, Nemet D. Usporedba pozitivnosti blasta za biljeg CD34 i mijeloperoksidazu u bolesnika s akutnom leukemijom, *Ibidem*, str. 56.
128. Labar B, Davidović-Mrišić S, Hitrec V, Nemet D, Bogdanić V, Radman I. Prognostičko značenje citogenetskih promjena u bolesnika s akutnom leukemijom, *Ibidem*, str. 57.
129. Sučić M, Boban D, Marković-Glamočak M, Bogdanić V, Nemet D, Labar B, Čvorišćec D, Plavšić F, Štoos-Veić, Mrišić M. Povezanost citomorfoloških promjena u urinu i terapije s ciklosporinom A u bolesnika s transplantacijom koštane srži, *Ibidem*, str. 57.
130. Radman I, Labar B, Kovačević-Metelko J, Bogdanić V, Nemet D, Zupančić-Šalek S, Mrišić M. Liječenje limfoma kože sistemnom kemoterapijom, *Ibidem*, str. 58.

131. Radman I, Labar B, Nemet D, Mrsić M, Kovačević-Metelko J, Bogdanić V. Uloga rekombinantnog humanog granulocitnog činitelja rasta u liječenju agresivnih ne-Hodgkinovih limfoma, Ibidem, str. 59.
132. Nemet D, Radman I, Labar B, Bogdanić V, Mrsić M, Skodlar J, Petrovečki M, Kovačević-Metelko J, Boban D, Kalenić S, Grgić-Markulin Lj, Sertić D, Zupančić-Šalek S, Serventi-Seiwerth R. Transplantacija autoložnih matičnih hematopoetskih stanica u liječenju malignih limfoma loše prognoze. Ibidem, str. 60.
133. Radman I, Labar B, Kovačević-Metelko J, Bogdanić V, Nemet D, Mrsić M, Čepelja Z, Boban D, Dominis M, Krajina Z. Djelotvornost kombiniranog liječenja kemoterapijom i ozračenjem u stadiju I i II Hodgkinove bolesti, Ibidem, str. 62.
134. Bogdanić V, Labar B, Mrsić M, Nemet D, Sertić D, Radman I, Maravić N, Šneller V, Zupančić-Šalek S, Kovačević-Metelko J. Liječenje teške aplastične anemije transplantacijom alogene koštane srži ili imunosupresijom, Ibidem, str. 67.
135. Labar B, Bogdanić V, Mrsić M, Nemet D, Vrtar M, Kerhin-Brkljačić V, Boban D, Dobrić I, Grgić-Markulin Lj. Liječenje kronične mijeloične leukemije transplantacijom koštane srži, Ibidem, str. 68.
136. Mrsić M, Labar B, Grahovac B, Bogdanić V, Hitrec V, Nemet D, Aurer I, Boban D, Dominis M. BCR/ABL gen određen tehnikom polimeraza lančanom reakcijom u bolesnika s kroničnom mijeloičnom leukemijom nakon transplantacije koštane srži, Ibidem, str. 68.
137. Mrsić M, Labar B, Radman I, Kovačević-Metelko J, Sertić D, Nemet D, Bogdanić V, Hitrec V, Boban D, Marković M, Sučić M, Davidović-Mrsić M, Klarin I. Liječenje bolesnika s mijelodisplastičnim sindromom, Ibidem, str. 69.
138. Mrsić M, Labar B, Bogdanić V, Nemet D, Dominis M, Kerhin-Brkljačić V, Hitrec V, Kalenić S, Maravić N. Liječenje osteomijeloskleroze transplantacijom alogene koštane srži - Prikaz slučaja, Ibidem, str. 70.
139. Nemet D, Batinić D, Užarević B, Skodlar J, Petrovečki M, Bogdanić V, Mrsić M, Kovačević-Metelko J, Sučić M, Golubić B, Bojanić I, Kalenić S, Labar B. Transplantacija autoložnih CD34+ matičnih stanica periferne krvi izdvojenih metodom pozitivne selekcije imunoadsorpcijskom tehnikom pomoću aparata Cephate SC (CellPro), Ibidem, str. 97.
140. Nemet D, Petrovečki M, Skodlar J, Mrsić M, Bogdanić V, Golubić-Čepulić B, Bojanić I, Batinić D, Užarević B, Boban D, Labar B. Transplantacija autoložnih matičnih stanica periferne krvi - evaluacija brzine hematološkog oporavka u usporedbi s transplantacijom stanica autologne koštane srži. Ibidem, str. 98.
141. Mrsić M, Labar B, Nemet D, Bogdanić V, Skodlar J, Batinić D, Golubić-Čepulić B, Maravić N. Liječenje raka dojke transplantacijom singene koštane srži - prikaz slučaja. Ibidem, str. 99.
142. Maravić N, Nemet D, Labar B, Bogdanić V, Mrsić M, Tomašković M, Skerlev M, Dobrić I. Ciklosporinom A izazvana reakcija presatka protiv primaoca nakon presaživanja autologne koštane srži. Ibidem, str. 99.
143. Kalenić S, Rebrović B, Francetić I, Senji P, Labar B, Nemet D, Bogdanić V, Mrsić M. Rezistentni enterokoki na hematološkom odjelu. Ibidem, str. 99.
144. Jandrić M, Kalenić S, Labar B, Nemet D, Jakić-Razumović J, Mrsić M, Plečko V, Bogdanić V. Invazivne mikoze dokazane na obdukciji kod ispitanika s malignom hematološkom bolešću. Ibidem, str. 100.

145. Labar B. Stem cell transplant as a postremission therapy for acute leukaemia. Abstract Book, 4th Seminar New Trends in the Treatment of Acute Leukemia, Brijuni Islands, September 1996, p. 36-38.
146. Bogdanić V, Labar B, Nemet D, Mrsić M, Aurer I. Allogeneic bone marrow transplantation in Croatia. Ibidem. 4th Seminar New Trends in the Treatment of Acute Leukemia, Brijuni Islands, September 1996, p 53.
147. Nemet D, Labar B, Bogdanić V, Mrsić M, Skodlar J, Petrovečki M, Batinić D, Maravić N, Radman I, Kovačević-Metelko J, Zupančić-Šalek S, Aurer I, Kalenić S, Sertić D, Boban D. Autologous stem cell transplantation for acute leukaemia in Croatia, 4th Seminar New Trends in the Treatment of Acute Leukemia, Brijuni Islands, September 1996, Abstract p. 54.
148. Mrsić M, Labar B, Nemet D, Bogdanić V. Cost of transplantation in Croatia. 4th Seminar New Trends in the Treatment of Acute Leukemia, Brijuni Islands, September 1996, Abstract p.59-60.
149. Zadro R, Nemet D, Mrsić S, Mrsić M, Stavljenić-Rukavina A, Bogdanić V, Radman I, Kralj D, Labar B. Molecular monitoring of the PML/RAR α fusion transcript in acute promyelocytic leukemia by RT-PCR. 4th Seminar New Trends in the Treatment of Acute Leukemia, Brijuni Islands, September 1996, Abstract, p. 65.
150. Maravić N, Nemet D, Bogdanić V, Mrsić M, Batinić D, Skodlar J, Tomašković M, Petrovečki M, Škerlev M, Labar B. Immune anileukaemia effect after marrow transplantation induced by CyA and buffy coat infusion. 4th Seminar New Trends in the Treatment of Acute Leukemia, Brijuni Islands, September 1996, Abstract, p.72.
151. Sučić M, Boban D, Marković-Glamočak M, Batinić D, Užarević B, Labar B, Nemet D. Determination of myeloperoxidase in patients with acute leukemia. 4th Seminar New Trends in the Treatment of Acute Leukemia, Brijuni Islands, September 1996, Abstract p.76.
152. Mrsić S, Batinić D, Boban D, Marković-Glamočak M, Sučić M, Stavljenić-Rukavina A, Labar B. Biphenotype acute leukaemia with translocation t(3;7)(q21;q43-45) - case report. 4th Seminar New Trends in the Treatment of Acute Leukemia, Brijuni Islands, September 1996, p.78.
153. Mrsić S, Labar B, Nemet D, Bogdanić V, Mrsić M, Radman I, Šalek-Zupančić S, Hitrec V, Boban D, Marković-Glamočak M, Sučić M, Stavljenić-Rukavina A. The prognostic significance of cytogenetic findings in acute myelogenous leukaemia. 4th Seminar New Trends in the Treatment of Acute Leukemia, Brijuni Islands, September 1996, p. 80.
154. Labar B, Nemet D, Bogdanić V, Mrsić M, Maravić N. Autologous versus allogeneic BMT for patient with acute lymphoblastic leukaemia in first complete remission. 4th Seminar New Trends in the Treatment of Acute Leukemia, Brijuni Islands, September 1996, p. 86.
155. Labar B, Nemet D, Mrsić M, Bogdanić V, Maravić N. Autologous vs allogeneic BMT for patients with acute myeloid leukaemia in first complete remission. 4th Seminar New Trends in the Treatment of Acute Leukemia, Brijuni Islands, September 1996, p. 87.
156. Nemet D, Batinić D, Užarević B, Skodlar J, Petrovečki M, Bogdanić V, Mrsić M, Maravić N, Sučić M, Golubić B, Bojanić I, Kalenić S, Labar B. Transplantation of autologous peripheral blood CD34+ cells positively selected using Ceparate SC

- immunoaffinity system or unmanipulated PBSC-comparison of engraftment. 4th Seminar New Trends in the Treatment of Acute Leukemia, Brijuni Islands, September 1996, p. 89.
157. Skodlar J, Nemet D, Gojčeta K, Batinić D, Užarević B, Mrić M, Maravić N, Golubić-Čepulić B, Labar B. The collection and evaluation of peripheral blood progenitor cells for autologous transplantation. 4th Seminar New Trends in the Treatment of Acute Leukemia, Brijuni Islands, September 1996, p. 90.
158. Labar B, Nemet D, Mrić M, Radman I, Skodlar J, Batinić D, Bogdanić V, Kovačević J, Aurer I, Petrovečki M, Golubić B, Bojanić I, Pisk M. Stem Cell Transplant for Aggressive Lymphoma – Zagreb Experience. 5th International Blood Cell Transplantation Symposium, Omaha NE 1997, Abstract 45.
159. Labar B, Nemet D, Mrić M, Bogdanić V, Radman I, Kovačević J, Zupančić-Šalek S, Aurer I, Pisk M. Liječenje akutnih leukemija starije životne dobi. Konferencija o problemima starijih osoba, Biograd na moru, 1998, str. 11.
160. Labar B. Stem cell transplantation for acute leukemia. XI Olomoucké Hematologické Dny s Mezinárodní účastí, Olomouc, 1998.
161. Richter D, Labar B, Batinić D, Kelečić J, Rajić Lj, Tješić-Drinković D, Mrić M, Hitrec V, Sertić J, Novak M. Dilemmas in Post-transplant X-SCID. ESID, Rhodes, 1998.
162. Labar B. Bacterial infections in neutropenic patients after intensive chemotherapy or stem cell transplantation. International Symposium on infection in Immunocompromised host, September 29-30, 1998, Dubrovnik, Abstract No 8.
163. Labar B. Viral infections after stem cell transplantation, International Symposium on infection in Immunocompromised host, September 29-30, 1998, Dubrovnik, Abstract No 9.
164. Labar B. Akutne leukemije – je li vrijeme za ciljanu terapiju. Liječ Vjesn. 2012; 134(supl 2):3-4.
165. Nemet D, Bojanić I, Serventi-Seiwerth R, Mrić M, Mikulić M, Golemović M, Golubić-Čepulić B, Labar B. Transplantacija krvotvornih matičnih stanica – kako dalje? 2012; Liječ Vjesn 134(supl 2): 55-57.

A.5. POZVANA PREDAVANJA

Predložnik je održao veliki broj pozvanih predavanja na međunarodnim i domaćim skupovima, te je bio voditelj većeg broja znanstvenih sekcija na znanstvenim sastancima i kongresima. Ovdje navodimo najvažnije:

- a) na međunarodnim skupovima više od 30 predavanja:
 - Godišnji sastanci Međunarodnog registra za liječenje transplantacijom krvotvornih matičnih stanica (International Registry for Blood and Marrow Transplantation - IBMTR) – Seattle, Honolulu;
 - Godišnji sastanci Europske grupe za liječenje transplantacijom krvotvornih matičnih stanica – (European Group for Blood and Marrow Transplantation – EBMT) – Barcelona, Lyon, Paris;
 - Američko Hematološko društvo (American Society for Hematology) – Atlanta;
 - Europsko društvo za Hematologiju (European Hematology Association) – Frankfurt;
 - Sastanci Nacionalnih hematoloških društava: Slovenije, Bugarske, Makedonije, Češke, Slovačke, Mađarske.

- Znanstveni skup: „New Trends in the Treatment of Acute leukemia“ Dubrovnik i „Leukemia and Lymphoma“ Dubrovnik.
 - Bio je gost predavač:
 - MD Anderson, Houston, Texas, USA
 - Mount Sinai Hospital. New York, USA
 - National Cancer Institute, Bethesda, Maryland, USA
 - Nebraska University, Omaha, Nebraska, USA
 - University of Utah, Salt Lake City, Utah, USA
 - Layden University, The Netherlands
 - Grosssharden Hospital, Munchen, Germany
 - Cantonspittal Basel, Switzerland
 - La Sapienca, Rome Italy
 - Saint Lousi Hospital, Paris, France
- b) na domaćim skupovima više od 50 predavanja:
- Nacionalni kongresi Hematološkog društva
 - Kooperativna udruga za liječenje hematoloških bolesti (KROHEM)
 - Nacionalna grupa za hematološke bolesti

A.6. STRUČNI RADOVI

Izradio je više od 20 kliničko-farmakoloških mišljenja o lijekovima vezano za njihovu registraciju. Napisao je i slijedeće stručne radove:

1. Bogdanić V., Čepelja Z., Grgić Z., Labar B.: Vrijednosti bakra, haptoglobina i alfa-globulina kod bolesnika od Hodgkinova bolesti liječenih po shemi MOPP. Zbornik radova, III kongres hematologa i transfuziologa Jugoslavije, Sarajevo, 1978, str 525-528.
2. Labar B., Flego I., Grgičević D., Pistotnik M., Grgić Z.: Vrijednost transfuzije krvi u liječenju anemičnih bolesnika praćena promjenama 2,3-difosfoglicerata. Zbornik radova. III kongres hematologa i transfuziologa Jugoslavije, Sarajevo 1978, str. 823-829.
3. Grgić Z., Piškorić D., Čepelja Z., Bogdanić V., Labar B., Ficović P.: Naša iskustva s uvodnom terapijom akutnih granulocitnih leukoza citozin-arabinozidom i adriamicinom. Zbornik radova, III Kongres hematologa i transfuziologa Jugoslavije, Sarajevo, 1978, str 189-191.
4. Labar B.: Transplantacija koštane srži. Izabrana poglavlja iz hematologije za liječnike opće medicine, Udruženje liječnika opće medicine Jugoslavije, 1985, str. 85-95.
5. Labar B., Bogdanić V., Plavšić F., Francetić I., Balabanić-Kamauf B., Grgičević D., Kaštelan A., Kerhin-Brkljačić V., Grgić-Markulin Lj., Boban D.: Prevencija reakcija transplantata protiv primaoca Ciklosporinom - preliminarni rezultati. Simpozij o Ciklosporinu, Dubrovnik, 1985., str. 41-48.

6. Labar B., Grgičević D., Bogdanić V.: Liječenje transfuzijama trombocita u hematologiji. Zdravstvo, Zbornik radova XIII međunarodne izložbe "Medicina i Tehnika", 1985, str.131-135.
7. Labar B.: Transplantacija koštane srži, Medicinska Enciklopedija, dopunski svezak, Leksikografski Zavod, Zagreb, 1986.
8. Labar B.: Bolesti matične stanice hematopoeze, Medicinska Enciklopedija, dopunski svezak, Leksikografski Zavod, Zagreb 1986.
9. Grahovac B., Stavljenić A., Labar B.: Phosphoglucomutase-1 isoforms as a genetic marker for bone marrow engraftment and hematopoietic chimerism after bone marrow transplantation *Biologie Perspective, Comptes Rendus du 7 Colloques de Pont-a-Mousson*. Ed. Galteau MM., Siest G., Henny J., John Libbey Eurotext, Paris, 1989, pp. 907-910.
10. Rajić Lj., Labar B.: Transplantacija koštane srži u djece, VIII Seminar Jugoslavenske Pedijatrijske [kole, Split 1991, Jugosl. Pedijatr., 34, suppl 1:49-52.
11. Gerhartz H.H., Marcus R., Delmer A., Zwierzina H., de Witte T., Jacobs A., Visani G., Fiere D., Sonneveld P., Labar B., Hoffbrand A.V., Fenaux P., Hayat M., Thyss A., Debucher L., Coiffier B., Sizoo W., Willemze R., Ribeiro M., Succiu S., Solbu G., Stern A., Zittoun R.: Randomized phase II study with GM-CSF and low-dose AraC in patients with "high-risk" myelodysplastic syndromes (MDS). in "Breakthrough in cytokine therapy: an overview of GM-CSF", ed. by Scarffe J.H., Royal Society of Medicine Services Limited, 1991, pp 27-40.
12. Gale RP, Labar B.: Croatia: Civilian hospitals as military targets, (letter) *Lancet* 339:48, 1992.
13. Labar B.: Robert Peter Gale visited Croatia, *Croatian Medical Journal, War Suppl.* 2, 33:234-235, 1992.

B. a) POPIS 10 NAJNAČAJNIJIH RADOVA PREMA OCJENI PREDLAGATELJA:

1. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, Hayat M, Stryckmans P, Rotoli B, Leoni P, Peetermans ME, Dardenne M, Vegna ML, Petti MC, Solbu G, Suci S for the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'adulto (GIMEMA) Leukemia Cooperative Groups: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia, *New Engl J Med* 1995, 332:217-223. IF 22,412, broj citata 618;
2. Suci S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B, De Rosa G, Belhabri A, Giustolisi R, Delarue R, Liso V, Mirto S, Leone G, Bourhis JH, Fioritoni G,

- Jehn U, Amadori S, Fazi P, Hagemeijer A, Willemze R. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CRI): an intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial. *Blood* 2003; 102:1232-1240. IF 10,120; broj citata 176;
3. Link H., Boogaerts M.A., Carella A.M., Ferrant A., Gadner H., Gorin N.C., Harabach I., Harrousseau F., Herve P., Holldack J., Kolb H.J., Krieger O., Labar B., Linkesch W., Mandelli F., Maraninchi D., Naprastek E., Nicolay U., Niederwieser D., Reiffers J., Rizzoli V., Siegert W., Vernant J.P., de Witte T.: A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high dose chemotherapy and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. *Blood*. 1992; 80:2188-2195. IF 8,061; broj citata 82;
 4. Ludwig H, Hajek R, Tóthová E, Drach J, Adam Z, Labar B, Egyed M, Spicka I, Gisslinger H, Greil R, Kuhn I, Zojer N, Hinke A. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. *Blood*. 2009; 113:3435-42. IF 10,555; broj citata 75;
 5. de Witte T, Suciú S, Verhoef G, Labar B, Archimbaud E, Aul C, Selleslag D, Ferrant A, Wijermans P, Mandelli F, Amadori S, Jehn U, Muus P, Boogaerts M, Zittoun R, Gratwohl A, Zwierzina H, Hagemeijer A, Willemze R. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukaemia following MDS. *Blood*, 2001;98:2326-2331. IF 9,273; broj citata 76;
 6. Oosterveld M, Muus P, Suciú S, Koller C, Verhoef G, Labar B, Wijermans P, Aul C, Fiere D, Selleslag D, Willemze R, Gratwohl A, Ferrant A, Mandelli F, Cortes J, de Witte T, Estey E. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. *Leukemia*, 2002;16:1615-21. IF 5,116; broj citata 21;
 7. Labar B, Suciú S, Zittoun R, Muus P, Marie JP, Fillet G, Peetermans M, Stryckmans P, Willemze R, Feremans W, Jaksic B, Bourhis JH, Burghouts JP, De Witte T for the EORTC Leukemia Group. Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients ≤ 50 years old in first complete remission: results of the EORTC ALL-3 trial. *Haematologica*. 2004; 89: 809-817 IF 4.192; broj citata 42;
 8. Mandelli F, Vignetti M, Suciú S, Stasi R, Petti MC, Meloni G, Muus P, Marmont F, Marie JP, Labar B, Thomas X, Di Raimondo F, Willemze R, Liso V, Ferrara F, Baila L, Fazi P, Zittoun R, Amadori S, de Witte T. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. *J Clin Oncol*. 2009; 27:5397-403. IF 17,793 broj citata 31;
 9. Bogdanic V., Nemet D., Kastelan A., Latin V., Petroveckí M., Brkljacic-Surkalovic LJ., Kerhin-Brkljacic V., Aurer I., Konja J., Mrsic M., Kalenic S., Labar B.: Umbilical cord blood transplantation in a patient with Philadelphia chromosome positive chronic myeloid leukemia, *Transplantation*. 1993; 56:477-479. IF 3,272; broj citata 32;

10. Labar B., Mrcic M., Pavletic Z., Bogdanic V., Nemet D., Aurer I., Radman I., Filipovic-Grcic N., Sertic D.: Prostaglandin E2 for prophylaxis of oral mucositis following bone marrow transplantation. Bone Marrow Transplant. 1993; 11:379-382. IF 2,234 Broj citata 52;

b), „impact factor“ (IF) ČASOPISA U KOJIMA SU RADOVI OBJAVLJENI(2012):

IF New Engl J Med	53,298
IF Blood	9,898
IF Blood	9,898
IF Blood	9,898
IF Blood	9,898
Leukemia	9,561
IF J Clin Oncol	18,372
IF Haematologica	6,424
IF Transplantation	3,272
IF Bone Marrow Transplantation	3,746

C. UKUPAN BROJ CITATA u SCI, CAB Abstracts

Ukupan broj citata je 2450;

D. BROJ RECENZIIJA PROJEKATA, KNJIGA, RADOVA U ČASOPISIMA

Dr Boris Labar recenzirao je projekte Ministarstva znanosti, školstva i športa u razdoblju od 2000 do 2004 godine iz područja Onkologije.

Dr. Boris Labar je međunarodni recenzent Javne agencije za raziskovalnu dejavnost Republike Slovenije za područje onkologije i hematologije 2010, 2011, 2012.

Dr Boris Labar je recenzent 6 udžbenika i knjige:

- Andolšek S. i suradnici "Hematologija" Slovenski udžbenik.
- Grgičević D. Transfuzijska medicina, Medicinska naklada Zagreb, 1995.
- Mišigoj-Duraković M. Tjelesno vježbanje i zdravlje, Grafos, Zagreb, 1999.
- Vuk T. Upravljanje kvalitetom u transfuzijskoj djelatnosti, Intergafika TTŽ, 2002.
- Šamija M, Nemet D i sur. Potporno i palijativno liječenje onkoloških bolesnika, Medicinska naklada Zagreb, 2010.
- Duletić-Naćinović A i sur. Hematologija, 2011.

Dr Boris Labar bio je recenzent:

- a) Međunarodnih časopisa: Bone Marrow Transplantation, Blood, Haematologica, Lymphoma and Myeloma;
- b) Domaćih časopisa: Liječnički Vjesnik, Libri Oncologici, Croatian Medical Journal.
- c) Sažetaka i prezentacija na kongresima: Europskog udruženja za liječenje transplantacijom krvotvornih matičnih stanica (EBMT), Europskog udruženja za hematologiju (EHA), nacionalnih kongresa.

E. UREĐIVANJE ZNANSTVENOG ČASOPISA

Dr. Boris Labar član je ili je bio član uredničkog odbora slijedećih časopisa:

Bio je član Uredničkog odbora *Croatian Medical Journal* i koordinator kliničkog dijela,

Bio je član Uredničkog odbora *Libri Oncologici*

Član Uredničkog odbora, odnosno regionalni urednik časopisa *Cancer Research Therapy and Control* (gl. urednik Samuel Gross) Harwood Academic Publishers Newark, USA.

Član Uredničkog odbora časopisa *Clinical Lymphoma*.

F. MENTORSTVO

Bio je mentor 5 magistarskih radova (Ž. Pečanić, M. Mrsić, J. Kovačević, M. Jandrlić, M. Sučić, S. Mrsić), te 10 doktorata (I. Aurer, A. Sinkovič, M. Sučić, M. Mrsić, M. Glaser, A. Boban, S. Mrsić, M. Martinović, B. Golubić-Čepulić, Z. Perić).

G. UTJECAJ NA RAZVOJ PODRUČJA/SPECIJALNOSTI

Predloženi je značajno utjecao na razvoj hematološke struke u nas i u svijetu:

- Godine 1983 uveo je u Hrvatsku liječenje transplantacijom alogenijskih krvotvornih matičnih stanica ponajprije zloćudnih bolesti krvotvornog sustava, teške aplastične anemije i brojnih nasljednih bolesti imunog i krvotvornog sustava. Time je ne samo pridonio značajno boljem liječenju navedenih bolesti već je i značajno utjecao na razvoj kliničke medicine. Za potrebe primjene transplantacije značajno su unaprijeđene ili osnovane slijedeće dijagnostičke i terapijske kliničke djelatnosti u KBC Zagreb: imunološki laboratorij, HLA tipizacija, patologija, transfuziologija, mikrobiologija ponajprije mikologija i virusologija, citogenetika i molekularna dijagnostika.

- Kao dugogodišnji voditelj Zavoda za hematologiju organizirao je odjel za liječenje alogenom i autolognom transplantacijom, odjel za primjenu intenzivne kemoterapije i Dnevnu bolnicu.
- Rad Leukemijske grupe EORTC-a u kojoj je sudjelovao kao središnji član objavljen 1995 godine u časopisu „New England Journal of Medicine“ s preko 600 citatata bitno je utjecao na primjenu alogene transplantacije u liječenju akutne mijeloične leukemije. Optimalno vrijeme liječenja, što vrijedi i danas je prva kompletna remisija bolesti nakon ciklusa intenzivne konsolidacije.
- U Zavodu za hematologiju (Bogdanić V. i sur.) po prvi put u svijetu provedeno je uspješno liječenje kronične mijeloične leukemije transplantacijom matičnih stanica iz krvi iz pupkovine
- Dr Labar je bio voditelj radne skupine EBMTG za zemlje u razvoju. Istodobno U hrvatskoj je osnovao Hrvatsku kooperativnu grupu za liječenje hematoloških bolesti KROHEM koju je koordinirao od njenog osnutka 2006 godine do danas. Dr Labar je osnovao i vodi međunarodnu kooperativnu grupu za liječenje leukemije srednje i istočne Europe - CELG (Central and Eastern European Leukemia Cooperative Group), sa sjedištem u Zagrebu.

H. OSNIVANJE KATEDRI, INSTITUTA, REFERALNIH CENTARA

Boris Labar je od 2000-2004 godine obnašao dužnost dekana Medicinskog fakulteta, Sveučilišta u Zagrebu. Zajedno s ostalim kolegama u to vrijeme potaknuo je i organizirao:

- Osnovao studij na engleskom jeziku, Medicinskog fakulteta, Sveučilišta u Zagrebu;
- U suradnji s Harvard Medical International, proveo edukaciju velikog broja nastavnika po načelu aktivnog pristupa učenju.
- Uvedena je obrana teme doktorskog rada.
- Osnovan doktorski studij i unaprijeđena kvaliteta trajne edukacije liječnika.

U Zavodu za hematologiju djeluju 2 referalna Centra:

- Referalni Centar za transplantaciju krvotvornih matičnih stanica
- Referalni Centar za nasljedne i stečene bolesti zgrušavanja

I. UDŽBENICI

Predložnik je napisao niz tekstova (preko 30) u Udžbenicima Interna medicina i Hematologija Medicinskog fakulteta i Farmaceutsko-biokemijskog fakulteta, Sveučilišta u Zagrebu. Važniji udžbenici kojih je bio urednik i tekstovi u udžbenicima navedeni su u poglavlju A. Knjige.

J. ORGANIZIRANJE ZNANSTVENIH SKUPOVA

Dr. Boris Labar bio je voditelj ili suvoditelj niza međunarodnih stručnoznanstvenih simpozija i seminara kao:

"*New trends in the treatment of acute leukemia*" Dubrovnik 1987., 1989. 1999 i 2001. 2004, Zagreb 1993., Brijuni 1996. Organizatori skupa su bili Europska Onkološka škola iz Milana i Zavod za Hematologiju, Klinike za unutarnje bolesti, Medicinskog fakulteta, KBC Zagreb. U tijeku je priprema sedmog znanstvenog skupa koji će se održati u rujnu 2004.

"*News in cytokines*", Beč, 1995. i 1999. Organizatori skupa Europska Onkološka škola iz Milana.

"*Stem cell transplants in solid tumors*" , Beč 1996. Organizator skupa Europska onkološka škola.

"*Infections in immunocompromised patients*" , Dubrovnik 1999., 2001., Organizator skupa Hrvatsko društvo za kemoterapiju.

„*Leukemia i Lymphoma*“ 2007, 2011 i 2015. Organizatori skupa MD Anderson Cancer Center, Houston, Texas, USA i Zavod za Hematologiju, Klinike za unutarnje bolesti, Medicinskog fakulteta, KBC Zagreb.

Dr. Boris Labar bio je predsjednik organizacijskog odbora I. Hrvatskog kongresa hematologa i transfuziologa s međunarodnim učešćem. Zagreb 1995. godine i predsjednik znanstvenog odbora II. Hrvatskog kongresa hematologa i transfuziologa s međunarodnim učešćem, Dubrovnik 1999.

K. NAGRADE I PRIZNANJA

Uz mnogobrojna priznanja i diplome, ovdje treba navesti:

- Nagrada grada Zagreba transplantacijskom timu i voditelju transplantacijskog tima Dr. B. Labaru za primjenu ove metode u Hrvatskoj (1984. godine),
- Nagrada Hrvatske akademije medicinske znanosti "Dr Ante Šerčer" za najbolji znanstveni rad 1998. godine.
- *CIBMTR 2013 Distinguished Service Award Recipient*. Za značajno unaprijeđenje znanosti na području transplantacije koštane srži u zemljama u razvoju, te zbog organizacije transplantacijskog programa.
- Počasni član Europske udruge za liječenje krvotvornim matičnim stanicama 2013.
- Nagrada grada Zagreba za životno djelo 2014. godine.
- Nagrada Hrvatskog sabora za znanost, za životno djelo iz područja biomedicine 2014/2015.
-

Dr Boris Labar počasni je član hematološkog društva Slovenije, Slovačke i Mađarske.

M. VODITELJSTVO ZNANSTVENIH PROJEKATA

Dr. Boris Labar sudjelovao je i vodio niz istraživačkih projekata vezanih uz transplantaciju krvotvornih matičnih stanica to su:

- Voditelj istraživač znanstvenog projekta br. SCF-02-092 Američko-Jugoslavenske suradnje (1981-1985. godine) pod naslovom: *CLINICAL AND EXPERIMENTAL BONE MARROW TRANSPLANTATION*.
- Glavni istraživač projekta *TRANSPLANTACIJA KOŠTANE SRŽI*, Ministarstva znanosti, republike Hrvatske (1985-1989. godine).
- Glavni istraživač projekta *CLINICAL BONE MARROW TRANSPLANTATION* Američko-Jugoslavenske suradnje, br. PN 917 1989-1990 godine.
- Glavni istraživač projekta Ministarstva znanosti republike Hrvatske, No 3-01-074, pod naslovom: *TRANSPLANTACIJA KOŠTANE SRŽI* (1991-1995. godine).
- Glavni istraživač projekta Ministarstva znanosti republike Hrvatske, Br. 108.133, pod naslovom: *KLINIČKA TRANSPLANTACIJA KRVOTVORNIH MATIČNIH STANICA* (1996 - 2002. godine.).
- Glavni istraživač projekta Ministarstva znanosti republike Hrvatske pod naslovom: *KLINIČKA TRANSPLANTACIJA ALOGENIH KRVOTVORNIH MATIČNIH STANICA* (2002 godina do danas)
- Glavni istraživač kolaborativnog projekta Ministarstva znanosti republike Hrvatske pod naslovom *GENSKA REGULACIJA I KONTROLA BOLESTI* (2003 godina do danas)

GRAD ZADAR

Odbor za dodjelu javnih priznanja

23000 Zadar, Narodni trg 1

PREDMET: PRIJEDLOG ZA DODJELU NAGRADE GRADA ZADRA

Predlažemo prof.dr.sc. Borisa Labara, priznatog stručnjaka i eksperta na području interne medicine i hematologije, za dodjelu Nagrade Grada Zadra za životno djelo.

Prilažemo suglasnost prof.dr.sc. Borisa Labara, životopis i potpise suglasnosti.

Predsjednik Udruge HULL
podružnica Zadar


HRVATSKA UDRUGA LEUKEMIA I LIMFOMI
10000 ZAGREB, Trg hrvatskih velikana 2
Tel./fax.: 48 73 561 . **3**

Boris Labar

Životopis

<u>Mjesto i datum rođenja:</u>	Zadar, 1947.
<u>Edukacija:</u>	
1965	Gimnazija u Zadru
1965-70	Medicinski fakultet, Sveučilišta u Zagrebu,
1971-72	Pripravnički staž, Klinička bolnica „Sestre Milosrdnice, Zagreb
1972	Poslijediplomski studij iz „Kliničko Laboratorijske korelacije“, Medicinski fakultet Sveučilišta u Zagrebu (1972-1975)
1972-76	Specijalizacija iz Interne medicine
1977	Asistent u Katedri za Internu Medicinu, Medicinskog fakulteta, Sveučilišta u Zagrebu.
1978	Magistar znanosti: „Klinička vrijednost određivanja metabolita difosfogliceratnog ciklusa i reduciranog glutationa u eritrocitu nasljednih hemolitičkih anemija“
1982	Doktorski rad “Piruvat kinaza u akutnih leukemija“
1982-85	Voditelj Centra za Transplantaciju koštane srži, Zavoda za hematologiju, Klinike za unutrašnje bolesti, Klinički bolnički centar Zagreb i Medicinskog fakulteta Sveučilišta u Zagrebu.
1982-85	Voditelj istraživač – znanstvenog projekta “ <i>Clinical and Experimental Bone Marrow Transplantation</i> ” No SFC-02-092N, USA-Yugoslav Joint fund
1982	Član Međunarodnog Registra za liječenje transplantacijom koštane srži (engl. <i>International Bone Marrow Transplant Registry – IBMTR</i>)
1982-90	Voditelj istraživač – znanstvenog projekta “Transplantacija koštane srži” Ministarstvo znanosti Republike Hrvatske.
1984	Docent u Katedri za Internu Medicinu, Medicinskog fakulteta, Sveučilišta u Zagrebu.
1985-2012	Pročelnik Zavoda za hematologiju, Klinike za unutrašnje bolesti KBC, Zagreb
1985-2012	Član Europske grupe za transplantaciju koštane srži (engl. <i>European Bone Marrow Transplant Group – EBMTG</i>)
1986-1989	Voditelj poslijediplomskog studija iz Hematologije, Medicinskog fakulteta, Sveučilišta u Zagrebu.
1987	Voditelj – Znanstvenog sastanka “ <i>New Trends in the Treatment of Acute Leukemia</i> ” organizatori Europska

- onkološka škola iz Milana, Italija i Zavod za hematologiju, Kliničkog bolničkog centra i Medicinskog fakulteta, Sveučilišta u Zagrebu
- 1987 Član međunarodnog društva za Eksperimentalnu hematologiju
- 1989 Voditelj – Znanstvenog sastanka “*New Trends in the Treatment of Acute Leukemia*” organizatori Europska onkološka škola iz Milana, Italija i Zavod za hematologiju, Kliničkog bolničkog centra i Medicinskog fakulteta, Sveučilišta u Zagrebu
- 1989 Voditelj istraživač – znanstvenog projekta “*Clinical Bone Marrow Transplantation*” No PN917 USA-Yugoslav Joint Fund
- 1990-2005 Izvanredni profesor iz Interne medicine, Medicinskog fakulteta, Sveučilišta u Zagrebu.
- 1991 Član osnivač Europskog hematološkog društva.
- 1991 Član Medicinskog savjeta, Europske onkološke škole, Milano, Italija, ureda u Beču.
- 1991-2005 Izvanredni profesor iz Hematologije, Farmaceutsko Biokemijskog fakulteta, Sveučilišta u Zagrebu.
- 1993 Voditelj – Znanstvenog sastanka “*New Trends in the Treatment of Acute Leukemia*” organizatori Europska onkološka škola iz Milana, Italija i Zavod za hematologiju, Kliničkog bolničkog centra i Medicinskog fakulteta, Sveučilišta u Zagrebu
- 1994 - 1998 Predsjednik Društva za hematologiju i transfuziju, Hrvatskog liječničkog zbora.
- 1995 Voditelj – Znanstvenog sastanka “*New Trends in the Treatment of Acute Leukemia*” organizatori Europska onkološka škola iz Milana, Italija i Zavod za hematologiju, Kliničkog bolničkog centra i Medicinskog fakulteta, Sveučilišta u Zagrebu
- 1996 Voditelj – Znanstvenog sastanka “*Stem cell transplants for solid tumours*” organizator Europska onkološka škola, ured u Beču.
- 1999 Voditelj – Znanstveni sastanak “*News in Cytokines*” organizator Europska onkološka škola, ured u Beču.
- 1999 Voditelj – Znanstveni sastanak “*Infections in Immunocompromised Patients*” Dubrovnik
- 2000 Počasni član hematološkog društva Mađarske i Slovenije.
- 2000 Član uredničkog odbora časopisa „Lymphoma”
- 2000-2004 Dekan, Medicinski fakultet, Sveučilišta u Zagrebu
- 2005-2012 Redoviti profesor iz Interne medicine, Medicinskog fakulteta, Sveučilišta u Zagrebu.

2007	Voditelj – znanstveni sastanak – „Leukemia and Lymphoma” organizator MD Anderson Houston I Zavod za hematologiju Klinički bolnički centra i medicinski fakultet Sveučilišta u Zagrebu.
2009-2012	Predsjednik Hrvatske kooperativne grupe za liječenje hematoloških bolesti – KROHEM
2010-2012	Predsjednik kooperativne grupe za liječenje leukemija srednje i istočne Europe (engl. „ <i>Central and Eastern European Leukemia Group</i> “ – CELG),
2011	Voditelj – znanstveni sastanak – „Leukemia and Lymphoma” organizator MD Anderson Houston I Zavod za hematologiju Klinički bolnički centra i medicinski fakultet Sveučilišta u Zagrebu.
2012-danas	Centar za ekspertnu medicinu, Zagreb.
2013.	Nagrada Međunarodnog Centra za istraživanje transplantacije krvi i koštane srži, Millwaukee, USA.
2013.	Počasni član Europskog društva za transplantaciju krvotvornih matičnih stanica.
2014.	Nagrada grada Zagreba za životno djelo
2014./2015	Nagrada za životno djelo Hrvatskog sabora u području biomedicinskih znanosti.
2015.	Voditelj – znanstveni sastanak – „Leukemia and Lymphoma” organizator MD Anderson Houston I Zavod za hematologiju Klinički bolnički centra i medicinski fakultet Sveučilišta u Zagrebu.
2015.	Profesor emeritus, Medicinski fakultet, Sveučilišta u Zagrebu.

Od 1974, publicirao je više od 405 znanstvenih i stručnih radova, s više od 140 znanstvenih publikacija u CC časopisima, koji su citirani 2450 puta.

Gost predavač u više institucija:

- Grosharden University Hospital Munchen
- The Fred Hutchinson Cancer Center, Seattle, WA, USA
- St Louis Hospital, Paris, France
- NCI, Bethesda, USA
- University Hospital, Salt Lake City, USA
- University Hospital, Leyden, The Netherlands
- Klinički Centar Ljubljana
- Hematologija, Katowice, Poljska
- MD Anderson Cancer Research Center, Houston, USA

Ostale aktivnosti:

1993	Član predsjedništva HAVK Mladost
1994-2001	Liječnik Hrvatske vaterpolo reprezentacije i vaterpolista Mladosti.
1996-danas	Predsjednik Zdravstvene komisije Hrvatskog olimpijskog odbora.
2005-danas	Član UO Hrvatskog vaterpolskog Saveza
2014-danas	Predsjednik HAVK Mladost

Zagreb, listopad 2015

Boris Labar, M.D., Ph.D.

Hrvatska udruga leukemija i limfomi – Podružnica Zadar

Velebitska 8

23 000 Zadar


PRIJEDLOG

Za dodjelu Nagrade Grada Zadra za životno djelo prof. dr. sc. Borisu Labar, priznatom stručnjaku i ekspertu na području interne medicine i hematologije.

Hrvatska udruga leukemija i limfomi – Podružnica Zadar

Predsjednik

Igor Blaslov



HRVATSKA UDRUGA LEUKEMIA I LIMFOMI
10000 ZAGREB, Trg hrvatskih velikana 2
Tel./fax.: 48 73 561

3

Liga protiv raka Zadar

Tajnik



Vladislav Tomčuk, dipl.



Hrvatska katolička udruga medicinskih sestara i tehničara

Predsjednica

Eva Zubović



Otočni sabor

Predsjednik

Denis Barić



Matica Zadraná

Predsjednica

Bukvić Milenka



UDRUGA DOBROVOLJNIH DARIVATELJA KRVI

KALELARGA

Borelli 12

23 000 Zadar

GRAD ZADAR

Odboru za dodjelu javnih priznanja

23 000 Zadar

Narodni trg 1

Predmet: Prijedlog za dodjelu javnih priznanja Grada Zadra za 2015. godinu

Povodom javnog Poziva za podnošenje prijedloga za dodjelu javnih priznanja Grada Zadra za 2015. godinu, kojeg je oglasilo Gradsko vijeće Grada Zadra pod posl.br. KLASA: 061-01/15-01/01, URBROJ: 2198/01-1-15-1 od 18. rujna 2015. godine, UDDK "Kalelarga" iz Zadra ovim putem predlaže Prof.dr.sc. Boris Labar i to za dodjelu Nagrade Grada Zadra za životno djelo.

Prof.dr.sc. Boris Labar, rođen 1947. godine u Zadru, priznati je stručnjak i ekspert na području interne medicine i hematologije, poznat i daleko izvan granica Hrvatske. Stručnjak za bolesti krvotvornog sustava, od slabokrvnosti, preko bolesti zgrušavanja i tromboze, do zloćudnih tumora krvotvornog sustava, leukemija i limfoma. Dugi niz godina na Rebru vodio je Zavod za hematologiju, Klinike za unutrašnje bolesti, KBC Zagreb i Medicinskog fakulteta, Sveučilišta u Zagrebu. Prof.dr.sc. Labar ima iskustva i znanja u primjeni svih oblika liječenja zloćudnih tumora krvotvornog sustava od primjene kemoterapije do liječenja transplantacijom krvotvornih matičnih stanica. Redovni je profesor Medicinskog fakulteta Sveučilišta u Zagrebu. Specijalist je interne medicine, uža specijalizacija hematologija.

Našoj Udruzi najbolje je poznato koliko je prof.dr.sc. Boris Labar učinio za pacijente koji su liječeni na Odjelu Hematologije u Klinici Rebro. Isto tako svjesni smo da je on svojim udžbenicima odgojio puno studenata na Medicinskom fakultetu u Zagrebu usmjeravajući ih upravo na zloćudne bolesti krvotvornog sustava.

Vjerujemo da je predloženi prof.dr.sc. Labar zaslužio Nagradu Grada Zadra za životno djelo, pa ga stoga i predlažemo.

U Zadru, 19. listopada 2015. godine

Za Udrugu dobrovoljnih
darivatelja krvi Kalelarga

Predsjednik Vjenceslav Jurin



U prilogu:


- suglasnost

BOVIS LABAR
HEGEDUŠIĆEVA 6,
10.000 ZAGREB

Zadar, 13. 10. 2015.

SUGLASNOST

kojom izjavljujem da sam suglasan i da prihvaćam prijedlog
UDDK KAVELARGA, za kandidata za dodjelu priznanja Grada Zadra.



POTPIS